Butterfly Network, Inc. — Call Transcript 2026

Hello, everyone, thank you for joining the Butterfly Network Inc. Q4 and FY 2025 earnings call. My name is Gabrielle, I will be coordinating your call today. During the presentation, you can register a question by pressing star followed by one on your telephone keypad. If you change your mind, please press star followed by two on your telephone keypad. I will now hand over to your host, John Doherty. Please go ahead. Good morning, thanks to all of you for joining our call today. Earlier, Butterfly released financial results for the fourth quarter and full year ending December 31st, 2025. We also provided a business update. The release, which includes a reconciliation of management's use of non-GAAP financial measures compared to the most applicable GAAP measures, are currently available on the Investors section of the company's website at ir.butterflynetwork.com. I, John Doherty, Chief Financial Officer of Butterfly, along with Joseph DeVivo, Butterfly's Chairman and Chief Executive Officer, will host the call this morning. During the call, we will be making certain forward-looking statements. These statements may include, among other things, expectations with respect to financial results, future performance, development and commercialization of products and services, potential regulatory approvals, revenue attributable to embedded collaborations through revenue share, chip purchases or otherwise, and the size and potential growth of current or future markets for our products and services. These forward-looking statements are based on current information, assumptions, and expectations that are subject to change and involve a number of known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those contained in the forward-looking statements. These and other risks are described in our filings made with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, and the company disclaims any obligation to update such statements. As a reminder, this call is being webcast live and recorded. To access the webcast, please visit the events section of our investor website. A replay of the event will also be available on this page following the call. I would now like to turn the call over to Joe. Thanks, John. Good morning, everyone, and thank you for joining our fourth quarter and full year 2025 conference call. I'm pleased to announce that our fourth quarter revenues came in at $31.5 million, growing 41% year-over-year. It's also the first quarter in our history where we realized positive operating cash flow, driven by upfront payments from our Midjourney deal. We are now nearly two years into our strategic growth plan that we introduced in early 2024. The message was clear: execute with focus and financial discipline, strengthen our core franchise, and unlock the full value of our semiconductor ultrasound platform beyond handheld devices. We're doing just that, and we now have material contribution outside of our core POCUS business. Earlier this month, Jim Cramer was asked a question about Butterfly Network on Mad Money, and he said, I quote, "It's a very competitive market, and I don't want to be in that part of the medical device group. Too hard for this guy, just too hard." You know, I'm a big fan of Jim Cramer, and like you, watch CNBC every day, and he's right about one thing: traditional medical devices are a tough sector, but Butterfly is not a traditional medical device company. We were never just a handheld company shaking at the knees of big ultrasound. We are David, faithful and committed to our cause, not backing down regardless of how large our opponent is. We are the disruptor. We are playing our own game with our own rules and our own playbook. We are digital eating analog's lunch and plan to revolutionize imaging with digital ultrasound everywhere and images taken. Goliath just doesn't know it yet. We are changing ultrasound imaging with our differentiated chip platform while deploying secure cloud software, AI tools, and mobile applications, and are the only healthcare company in the world over the last seven years to receive an Apple Design Award. We are not a medical device company alone. We are a transformative semiconductor-based ultrasound company. As you're all aware, the strategy we introduced has three core tenets: accelerate our core POCUS business with an enterprise-ready, cloud-connected imaging solution, execute strategic initiatives to reach new care settings and enable entirely new applications, namely home care and Ultrasound-on-Chip co-development. Lastly, deliver an R&D roadmap that sharpens our technology edge with next-generation chips and new form factors getting more and more powerful and capable. Let me walk you through the progress in each of these. In core POCUS, revenue grew 15% year-over-year on top of a 35% growth in the fourth quarter of last year, which, as you recall, was a record product launch year. We closed a second large system-wide enterprise deal in the fourth quarter of 2025 and continue to deepen medical school and enterprise relationships. I'll let John cover the financials in more detail, but we feel much better about macro trends and the deal cycle than earlier in the year and expect to carry that momentum into 2026. The fourth quarter Compass AI launch is a big tailwind for our enterprise strategy. Enhancing our enterprise solution helps refresh existing accounts, continue attracting new customers and drove more than 50% growth in our enterprise pipeline since launch. At the same time, we've been building what we believe is one of the most secure cloud infrastructures in healthcare. In the U.S., we most recently achieved GovRAMP and TX-RAMP, and FedRAMP is anticipated in the coming months, meaning we'll soon be even more qualified for cloud deployments in now the world's largest government market. Internationally, we see meaningful opportunities in 2026 as we open markets in South America and continue expanding across Middle East and Asia, alongside a renewed momentum in global health. We've surpassed 1,000 NGO partners worldwide, and many expect to increase activity in 2026. We also continue to make progress in our Butterfly Garden partners, and as you know, HeartFocus became the first FDA-cleared app in 2025, and we expected additional partners to reach that clinical milestone in 2026. We announced plans to release our proprietary beam steering API in the first half of this year. The API will open 3D imaging capabilities that have been reserved for Butterfly products only. Because our beam steering is fully digital on a semiconductor chip and not mechanically driven like other legacy systems, we can uniquely extend those capabilities to partners. The goal is to advance what they can build, expand the AI ecosystem, and help accelerate ease of use. We're excited about the new opportunities this welcomes. Moving to the strategic growth engines. We've built a home business determined to accelerate the use of POCUS devices where the patient is, expanding the reach and empowering nurses and other clinicians to perform scans using AI tools. I believe we will reach a commercial agreement in 2026, allowing home care to enter its commercial phase. This is a powerful new channel that reduces hospital readmissions, lowers costs, and expands Butterfly's reach beyond the hospital. Home care is a reality, we think it can be a real growth driver, starting to add revenue in late 2026 and into 2027. We also ventured out to develop a new business to make our core Ultrasound-on-Chip available to companies with large new market opportunities that are not competitive with Butterfly's focus business. That was previously known as Octave. Well, to start the new year, we've officially sunset the Octave name and have centralized our semiconductor platform strategy under Butterfly Embedded, reminiscent of the Intel Inside model. What began as an adjacent effort is now emerging as a foundational business, enabling other category-defining innovators to build entirely new application on Butterfly's Ultrasound-on-Chip technology. The big news for the fourth quarter, though, was signing Midjourney deal in November, and as you can see today, it contributed $6.8 million of revenue in the quarter and was a key driver of our 41% year-over-year growth. Midjourney is an independent research lab pushing the boundaries of generative AI and human imagination. Their scientists have envisioned a breakthrough new application for ultrasound that we believe the world will be learning about very soon. This partnership combines Butterfly's core Ultrasound-on-Chip technology and imaging software with Midjourney's generative AI compute power to do something very special with ultrasound. This deal is more than revenue, it is validation. It's a foundational step towards Butterfly's reinvention into a platform company. The initial partnership and revenue contribution is pre-commercial. Based on the plan that Midjourney has shared with us, once commercial, we believe there is meaningful additional revenue opportunity for Butterfly in the form of chip sales and revenue share on top of the licensing fees that will continue through the deal. We expect this to happen in the outer years of our five-year plan, and if it occurs, could represent meaningful progress towards our goal of reaching $500 million in annual revenue by 2030. Beyond Midjourney, we signed an additional Butterfly Embedded research share partner this quarter and expect another one shortly, while managing an active pipeline of some of the largest technology and healthcare companies in the world. Before I look ahead to our R&D roadmap initiatives, I'll turn it over to John to discuss the financials. John? Thanks, Joe. I'm very excited to have joined Joe and the talented team here at Butterfly, which includes Megan Carlson. Megan, who you all know, did a great job in the interim CFO role and has been an awesome partner to work with, along with the rest of the leadership team. With about three months behind me, I want to open with a few comments and my thoughts on Butterfly overall. I joined Butterfly because I was excited by the incredible potential this company has going forward to provide a valuable and meaningful experience to our customers, as well as to create value for our shareholders. I was also impressed by the strength of the leadership team and the passion and commitment demonstrated by employees across the company. This is a company I am proud to be a part of. Butterfly certainly navigated a few challenges in its early years as a public company. However, the company has made the necessary difficult adjustments, including improving its operating efficiency, choosing the markets it can win in, selecting the best ways to leverage its IP and technology advantage, and allocating its resources towards higher ROI opportunities and markets. No doubt, based on these actions, Butterfly is a stronger, more agile company today. With continued steady execution, the company has the potential for significant core growth in an incredibly meaningful domain through its focused and related conscious AI software and Butterfly Garden business, and we are well positioned to gain outsized share in the markets that we compete in. We also have a significant opportunity to leverage our core platform of Ultrasound-on-Chip into other nascent and disruptive markets consistent with our strategy through Butterfly Embedded, as the Midjourney partnership demonstrates. With that, let's move on to a few highlights for the fourth quarter, including a record level of revenue for the quarter and exceeding the high end of our total revenue and adjusted EBITDA guidance ranges, a record level of quarterly probe sales, significant improvement in adjusted EBITDA margin, driven by our revenue performance and continued financial discipline, the lowest annual cash use in the company's history, and we generated positive free cash flow in the quarter, and the execution of the Midjourney contract, which helps to solidify and amplify all of our efforts to drive a new wave of ultrasound-enabled platforms and use cases through Butterfly Embedded. Let me move on to our results. We had a strong fourth quarter of 2025, with revenue of $31.5 million, the highest quarterly result in the company's history. This represents a 41% increase year-over-year for the quarter. The increase is driven by increased revenue from Butterfly Embedded, as well as a 27% increase in year-over-year volume in our core focused business, with continued penetration of the iQ3 in all markets. The 41% year-over-year growth is significantly higher than the at least 17% year-over-year growth that we put out in January. We did better in the core business and realized more revenue from Butterfly Embedded, given the work we had already performed relative to the Midjourney contract. This is the primary reason we used the at least language at the time, as we were still finalizing the accounting treatment. Our results and the guidance I'll provide later in the call for first quarter and full year 2026 all include updated financial expectations from this contract. Breaking things down between the U.S. and international channels, during the quarter, U.S. revenue was $26.8 million, which was 55% higher year-over-year, driven by revenue from Embedded, as well as strong demand in the core business, with unit sales up 44%. Total international revenue decreased by 6% year-over-year to $4.7 million in the fourth quarter. While sales of the iQ3 in the quarter were up 42% year-over-year, sales of the iQ+ were down 79%. Breaking our revenue down between product and software and other services, product revenue was $18.1 million, an increase of 23% versus the fourth quarter of 2024. This increase was driven primarily through growth in volume across all channels, with US health systems, e-com, and vet leading the way, as well as higher average selling prices in international markets with the higher mix of iQ3 sales. Software and other services revenue was $13.4 million in the fourth quarter, up 76% year-over-year. Software and other services mix was 43% of revenue, increasing from 34% in Q4 2024. This increase can be attributed to the significant step-up in revenue contribution from Butterfly Embedded in the quarter, related primarily to the Midjourney partnership. I'll talk more about this as well when I come to guidance for the first quarter and full year 2026. When looking at the full year 2025 versus 2024, total revenue increased 19% to $97.6 million. This was driven by two areas. First, growth in our core focused business, with both increased volume and a higher average selling price, driven by an increased mix in the sales of the iQ3 and strong performance by U.S. sales, our vet channel, and international distributor channels. Second, growth in our emerging Butterfly Embedded business, primarily from the execution of the Midjourney contract in November of last year. Moving on to gross profit. Gross profit was $21.2 million in Q4 2025, a 55% increase as compared to the prior year adjusted gross profit of $13.7 million. Gross profit margin percentage increased to 67% from 61% in the prior year period. Gross margin percentage was positively impacted by the higher-margin Butterfly Embedded revenue and lower software amortization. Moving to EBITDA and cash. For the fourth quarter of 2025, adjusted EBITDA loss was $3.2 million, compared with a loss of $9.1 million for the same period in 2024, an improvement of 65%. For the full year 2025, adjusted EBITDA loss was $26.5 million, compared to $38.9 million for 2024, an improvement of 32%. The improvement in adjusted EBITDA loss for both the fourth quarter and full year was driven by contribution from higher margin revenue and continued financial discipline reflected in our lower year-over-year payroll costs for the quarter and full year. This improvement in adjusted EBITDA and continued financial discipline has led to a cash and cash equivalent balance, including restricted cash at year-end of $154.5 million, and the use of cash in 2025 of $19.4 million, excluding the funds from our offering last year. This compares to a use of cash of $45.9 million in 2024, an improvement of $26.4 million. We also had positive cash flow of $6.3 million in the fourth quarter. These results demonstrate that we are very well positioned as we move forward to continue to invest in the business areas where we see significant opportunities for additional growth and disruption, including expanding our core POCUS business and penetration of Compass AI as a core operating system for health systems. Continuing to enable third parties to build tailored ultrasound AI solutions in Butterfly Garden to provide deeper and expanded access to our platform. Expanding our home care business following the execution of our anticipated first commercial agreement, which we believe could be finalized in the first half of 2026, as Joe mentioned earlier. Enabling a new wave of Ultrasound-on-Chip-enabled technologies through Butterfly Embedded, and continued AI and semiconductor innovation with the development of our 4th-generation chip. Before turning to guidance, I want to update you on the general macroeconomic environment relative to Butterfly. While there were some concerns in 2025 relative to the government shutdown and impact on the FDA's processing of fee-based submissions, regulatory processing delays, and delays in customer purchasing decisions, we have managed through this, and it is very much behind us. Our fourth quarter results are indicative of that, and we were able to close some of the larger deals in the pipeline and still have a number that are active. I would now like to turn to our outlook for the first quarter of 2026 and for the calendar year ending December 31st, 2026. In the first quarter, we expect revenue in the range of $24 million-$28 million, as we ended the fourth quarter somewhat higher than expected, and the first quarter is typically a slower quarter for the company due to seasonality. As is typical for Q1, adjusted EBITDA is impacted from expenses related to payroll tax and 401(k) reset, as well as our national sales meeting and POCUS Innovators Forum, which took place in January. As a result, we expect slightly higher expenses and higher adjusted EBITDA loss in the first quarter relative to the remainder of the year in the range of $8 million-$10 million. For the full year 2026, we expect revenues to be between $117 million and $121 million, an increase of approximately 20% to 24%. We expect our adjusted EBITDA loss to be between $21 million and $25 million. Our guidance for adjusted EBITDA includes investment in key areas to support continued innovation, as well as our emerging embedded business, as well as the impact from tariffs initiated in 2025. In summary, we had a great quarter, a record quarter. We closed the year out strong, we exceeded expectations for revenue and adjusted EBITDA, and we are very well positioned going forward. As our 2026 full year guidance indicates, we look forward to continued growth this year and beyond, and our overall outlook on the business is brighter with this past quarter reinforcing our view. In 2025, we believe the company enhanced its position in the core POCUS markets and can continue to gain share in 2026 through deeper penetration of existing customers, new customers, and applications. We also amplify our Ultrasound-on-Chip platform and the potential of Butterfly Embedded with the licensing partnership with Midjourney. We did all of this while continuing our intense focus on driving operating efficiency across the business and ROI. As I said up front, I'm excited to have joined Butterfly late last year, and I'm excited about what is ahead for the company in 2026 and beyond. Now, let me hand it back to Joe for some closing comments. Thanks, John. It's an exciting time for Butterfly. We're in a strong position and are delivering on all fronts. The future is even brighter. Before closing, I'll touch briefly on R&D. We recently spent two days with 60 leading POCUS thought leaders at our annual POCUS Innovators Forum, and the alignment was unmistakable. The goals, needs, and future state vision shared was directly in line with where we are taking our portfolio. That level of synergy only strengthened our conviction that we have a path to enable every doctor and nurse with powerful, affordable, compact imaging and can meaningfully unlock enterprise adoption. As I mentioned on the last call, our fifth generation P5.1 chip was moved to production by year-end. We're excited in achieving harmonics and delivering a new level of imaging for handheld ultrasound. This will open additional subspecialties and support our enterprise selling efforts in 2027 and beyond. Next up on our chip roadmap is Apollo. This new chip architecture is now receiving the full attention of our engineers and will deliver 20 times the current data rate and compute performance, ushering in a new era of digital imaging and AI. We are already working with several Butterfly Embedded partners based on the capabilities of this platform. I'd like to close by sharing exactly why I'm so excited about Butterfly's current chapter. We are pioneering semiconductor-based digital ultrasound everywhere it's needed. In the traditional ultrasound market, that means continuing to lead in point-of-care solutions that truly meet the demands in and out of the hospital, empowering doctors, nurses, and caregivers, expanding new subspecialties, strengthening our enterprise roadmap, moving imaging to the bedside and beyond it. It's also bigger than that. Ultrasound is being researched and deployed in brain therapy, continuous monitoring, robotics, organ preservation, and the list goes on. If you do a simple search of ultrasound in the magazine Nature, just this month alone shows applications in neuromodulation, ablation, antiviral therapy, and soft robotics. The real inflection point comes when ultrasound in these use cases move to silicon, when it becomes programmable, power efficient, AI native, scalable. That's the common thread. Whether it's a Butterfly handheld in a clinician's pocket, a new form factor on our roadmap driving enterprise or home adoption, or a partner building something novel with our technology that we can never do ourselves, it's the same core technology, the same architectural advantage. We are not just building devices, we are opening markets. We are enabling a new age of digital ultrasound imaging and sensing, all in one strategy. This is Butterfly. We're not just a medical device company. We're a true disruptor building the ultrasonic backbone of the AI era and one of the most exciting technology growth stories in healthcare and technology today. With that, operator, please open it up for questions. Thank you, Joe. To ask a question, please press star followed by one on your telephone keypad now. If you change your mind, please press star followed by two. When preparing to ask your question, please ensure your device is unmuted locally. Our first question is from Josh Jennings from TD Cowen. Your line is now open. Please go ahead. Hi, good morning. Thank you. Impressive to see all the progress in so many different channels. Gives us a lot to ask about, challenging to choose one of those lanes, wanted to start with Butterfly Embedded. Thanks, Josh. Absolutely, just wanted to better understand, and you may not be able to share, but any details around potential timing of the technology offering that Midjourney is going to put forward, implementing Butterfly's semiconductor and ultrasound chip technology? Any help just thinking about the cadence of revenue contributions from this partnership over the course of 2026 and what's embedded in guidance? Well, I'll let John answer the second part of that in a moment. Let me just get to the first. I think we're probably gonna see something, you know, in the relative near term from Midjourney. You know, one of the things about a Butterfly Embedded program is we are enablers for our partners. This is not our business, this is their business, and we do everything we can to amplify their business. I don't wanna get out ahead of them, and all I wanna do is do everything that we possibly can as a partner to support them. That said, I think, you know, they probably wanna get this out sooner rather than later. The moment they do, you know, we'll do the best to show you how it, you know, translates into Butterfly. John, do you want to take the second part of that? Yeah, sure. Thanks, Joe. Appreciate it. How you doing, Josh? Good. So- Thanks a lot. When you look at Embedded, you know, obviously, yeah, as Joe touched on during the opening remarks, Midjourney kind of lit it on fire, if you will, with the contract we signed at the back end of 2025. We're very excited about that contract. There's also, you know, a number of other partners that we're working with in Embedded. While right now, Embedded and our revenue is, you know, there's a big contribution from Midjourney, we do expect, you know, other contributions from other partners that we have in there, and, you know, we're really excited about what that part of our business can be, as we discussed at the back end of 2025. You know, relative to Midjourney, it's a $74 million contract, as we mentioned. There's different components of it. You know, there's the upfront payment, there's annual license fees, and then there's milestone work that we do that ultimately, you know, allows us to, you know, do the, you know, take the revenue, ultimately, you know, quarter by quarter, if you, if you will, year by year. You know, we expect to get a good amount of contribution throughout 2026 into 2027 from the contract. In addition, when they commercialize, ultimately, you know, as Joe mentioned upfront as well, there's an opportunity for chip sales as well as for a revenue share as part of their business. Ultimately, really excited about the overall contribution from Midjourney, but Embedded is not just Midjourney. No, I appreciate that answer, and kind of leads into my next follow-up is, I mean, our understanding is that the team was focused on the Midjourney partnership and development work and then locking that in in 2025, but there were some other potential partnerships on the periphery that sounds like you guys are engaged and moving forward. Any help thinking about the Butterfly Embedded pipeline that you just referenced? Yeah. I mean, we're talking to a lot of people. As I mentioned, some, you know, very large organizations and also a lot of startup organizations. Kind of the way it works is, you know, we saw a, you saw a contract in the 8-K with Midjourney, in November of 2025. They had been an embedded partner for over a year prior. So the way it kind of works is, you know, people will buy a license to our software, and then they'll start buying chips, and they'll do some research. They'll do research, you know, as far as how does, you know, does a chip meet their performance that they need? How does it integrate with their systems? Then, and they do a bunch of work. You know, whenever they're done and ready, you know, if everything worked out well, then it will turn into a commercial agreement. They'll come back and say: "Okay, well, we want to now do, you know, X, Y, and Z." That's kind of how Midjourney happened. There's really no formula. It's just, you know, we have, I think, now, eight or nine embedded partners today, and the pipeline is pretty large. It's also, you know, we're not selling off-the-shelf product. You know, we have to take our product, and we have to do labs and show them how it can fit with their tech and whatnot. It is a bit of a sales process, but, you know, do we have another Midjourney in there? I hope. You know, there are some very big opportunities people are going after, massive opportunities, actually. You know, we're gonna continue to add people into the research phase of our relationships and do everything possible to meet their needs and get them, you know, committed to a commercial phase, like Midjourney did. Excellent. Maybe one question on the home care franchise, and it sounds like you've made progress in this first commercial partnership. I mean, what steps are left before that commercial effort kicks in? Maybe just remind us of the home POCUS market opportunity or the revenue opportunity for Butterfly in this channel. Thank you, guys, for taking all the questions. Hey, thank you, Josh. Appreciate them. Yeah, I think, you know, we're pretty confident that this is going to, you know, get to a commercial conclusion. You know, as John said, in his notes, we think it'll probably happen before middle of the year, which will give us the second half of the year, to start getting it ramped up. It'd probably be nominal revenue in 2026, but start contributing in 2027. Once we get it started, and we have a line of sight, and we're able to give a better shape of what the impact is, we'll tell you as far as, you know, and incorporate it into our guidance. You know, in aggregate, I think I've mentioned in the past, you know, if just this one use case we're working on, if it became a national use case, it could be a $40 million-$50 million revenue opportunity if everything went, you know, the way that we saw it. That's. You know, when we think about the amount of chronic care patients are in nursing homes and also the amount of patients that are in the home, who are being cared for by nurses, you know, as they get sicker, they need to be, you know, moved. They need to have an image. You know, they have to go to the hospital, whether it's by ambulance or by some other transport, be brought up into radiology and then have, for example, a cardiac echo or something else. You know, empowering caregivers to be able to take images where they are is efficient, is low cost, and has high impact on being able to quickly give a diagnosis for a patient so their meds can be modified to make them healthier and keep them into the home, or keep them wherever they are. That is literally every facet of healthcare is about being where the patients are, being where people are, and helping them get healthier faster in the lowest cost environments. You know, our home care business is basically an extension of our POCUS business. It's not a third business; it's an amplifier of POCUS. You know, ultimately everyone will figure it out, and they'll use our stuff to do all of this using the AI apps, et cetera. Home is kind of a catalyst for us to, you know, take a lot of the workflow, the logistics, and the ramp-up and the learning curve out. I've mentioned before that we think the home business can be bigger than POCUS, and the opportunities are certainly there. We have, you know, we have to prove it, and we have to get some more. Our pilot was excellent. We need to get, you know, the first few states up. We need to prove what we're doing there. We need to prove we can go to a larger geography. It's a process, but it's a big opportunity, and it'll teach, you know, core healthcare providers and payers that point-of-care ultrasound with Butterfly is a significant way to reduce costs at the exact same time of improving quality and care for patients. Thank you, Josh. Our next question is from Chase Knickerbocker from Craig-Hallum. Your line is now open. Please go ahead. Good morning, guys. This is Jake on for Chase. I was wondering if you could, maybe, John, if you could give us any more color on the macro environment, if you guys are seeing any of the same trends, that affected 2025 and how they're abating now in 2026? Sure, and I appreciate the question. As I touched on, you know, with the opening comments, I'm not gonna say everything's behind us, but certainly, you know, we feel, you know, a lot more confident going forward. Irrespective of the Supreme Court's action relative to tariffs, you know, it's still a very. mild, say mildly, and an unpredictable area, given what happened post that. You know, we do still expect to have a bit of some downward pressure. Not a lot, but some downward pressure from tariffs. We did sign a number of contracts late in the year, so we see that things have been opening up a bit there. We still have a number of, you know, good-sized deals in the pipeline. I'd say, you know, the timing did move out kind of the back half of last year as the company had touched on when they did third quarter results, but we are seeing some improvement there. We're starting to see some things move. Ultimately, as I mentioned, you know, the company, we're managing through it, and we don't expect it to have except for the, you know, the tariff component, we don't expect it to have a lot of impact on the company. Great. I appreciate that color. Apologies if I missed this, but is there any more color on the opportunity with medical schools going into the year as well for the one-to-one partnerships? Yeah. Medical schools, I think, should be a pretty, a pretty strong contributor to us this year. You know, the, you know, second quarter of the year is the big medical school quarter when we, when we put them all in. We have a lot of conversations for one-to-one buys, and you know, we did get a bit of a pause last year when the decision to cap student loan debt occurred, and so it caused people to pause. You know, what's so exciting about what we're doing is there is such a strong commitment for new medical students to learn ultrasound. They're actually now starting to choose where they go and the types of programs they get into based upon the commitment of building that competency. You know, kids that are graduating today, and are going into their residency, completely distinguish themselves when they have this capability. Even, you know, even their, you know, their attendings, who are working with them, you know, are kind of, surprised when they see what can be done by a resident with ultrasound skills. There's not a lot of daylight out there. This is not a new thing. Students want Butterfly. They're trained on Butterfly. They want that experience, and then when we build the brand equity with these students, they go into their residency and then into practice with that loyalty, with that understanding, and we're looking to grow with them, especially, you know, with our whole, you know, chip platform improving and getting more and more powerful, and then more apps coming in over the years. You know, we're gonna grow with them through their career. We start off with medical schools. Medical schools will be a very positive contributor in 2026. Appreciate the answers, guys. Thank you. Thanks, Jake. Thank you. Our next question is from Andrew Brackmann, from William Blair. Your line is now open. Please go ahead. Hey, guys. Good morning. Andrew. Thanks for taking the questions. I'll echo Josh's comments. Certainly a lot of progress here and a lot to dig into. Joe, maybe with that in mind, I'd like to start a little bit higher level. I mean, it's sort of hard to miss the underlying transformation going on here, towards Butterfly Embedded. Can you maybe just sort of talk to us about why now for this transition from med devices towards embedded and the semiconductors type of business? Then just as you sort of think about organizational focus, perhaps, are there any sort of changes in terms of your view on focus versus the opportunity with Embedded? Thanks. That's a great question, Andrew, and I actually, I probably should have emailed that to you and planted that in, because it's, that's a very appropriate question. You know, we're not trying to pivot away from focus. You know, we, you know, we wanna have every doctor and every nurse in the world, have a device that allows them to help diagnose their patients sooner, easier, low cost, where they're at. We will never, you know, move away from that vision. You know, in accomplishing that vision, Andrew, we solved the problem. We solved a major problem in technology where we can digitize, we can digitally control the ultrasound image. We can control it in a way that is much more than what medical ultrasound uses with, you know, multiple planes and depths. Because we control 9,000 sensors in a rectangle, which allow us to send out information, send out sound a certain way, and listen to sound a certain way. You know, what we solve for ourself for point-of-care ultrasound is a major solution for many other people out in the marketplace. You know, there is this whole concept that AI and the human body are going to merge together. You can Google it. There's a whole sci-fi fantasy out there. You know, there. If you even think of brain-computer interface, you know, Neuralink today is putting wires into the brain. There's this thing in BCI called the butcher factor, which is, you know, how many neurons do I have to kill before I get to the neuron I want to talk to? Well, one of the beautiful things about ultrasound is, and about Butterfly, is we don't have a stagnant beam that sits in a fixed position. You know, normally, ultrasound's like a flashlight. You know, you have to move the beam in order to capture the image. We can actually, in a fixed location, move our beam and scan. If you implant something in the brain, you're gonna be able to communicate and see and listen to 25% of the entire brain or the entire lobe. It's being seen today that ultrasound is potentially a portal between AI and the human body. Just read Nature and you'll see all these articles about brain-computer interfaces, and you'll hear about ultrasound, you'll hear about neuromodulation, you'll hear about all different types of, you know, even if it's therapeutic, people are going to be looking at the brain signals through vasculature and how vasculature flows through the brain. It ultimately, you know, you can potentially heat it and put energy. This is kind of happening. It's not like we just did a prospect, a randomized study, and we're now pushing the market. The market's calling us. They see our 600 patents, they see the excellent technology that we have, and quite frankly, we have been approached prior to me getting here by companies asking to partner with them, but they were turned away because the company was trying to focus on point-of-care ultrasound. What we've said to ourselves is, "No, we've solved the foundational problem." you know, I'd hate to compare ourselves to NVIDIA because there's no way there's a scale or anywhere to draw a line. you know, from 93 to 2005, they were a video game company, and they focused on their core markets of building technologies to be better gamers, that had to be complex. You know, and then with CUDA in 2006, it opened up their platform for developers who could use these incredible chips for other applications. You know, or you look at Amazon, you know, they didn't set out to become the leading cloud compute company in the world. They realized that they needed cloud compute. There wasn't a large enough vendor to take their volume. They built it themselves. When they were done, they had excess capacity, and they said, "Let's go sell that capacity." Now it's the highest profit-generating part of their business. Sometimes in business, you solve problems for your customers that benefit others, and we're just simply now allowing ourselves to work with those partners. The beautiful part about it is that the roadmap that we've set ourselves, so, you know, our Poseidon platform, our P5.1 platform, our Apollo platform, we are now not going off and developing new things for other people and losing our focus on Point-of-Care Ultrasound. What we're actually doing is amplifying our current roadmap, and we're exposing our roadmap to those customers and those and to allow them to meet their needs. It actually is going to make our ability to serve point-of-care ultrasound better, and the roadmap that we have for point-of-care ultrasound and what's going to happen, you know, with our next launch of our platform, with Harmonics and P5.1, and what we're going to do with, you know, some new things that we'll unveil in 2027, there's so much synergy here, Andrew. It all ties together. We're not putting something on the shelf and then focusing someplace else. We're pulling our core tech, we're partnering with people who have real interest of building businesses and have technical challenges that we can solve. Instead of having an analog ultrasound device that, you know, yes, you have digital behind the lens, but then once you push the signal through the lens, that lens is cut to do one thing. Our lens can be anything, and developers love the fact that they can see the signal and then change the software, see the signal, change the software. That, you know, kind of infinite iteration cycle is how, you know, we will fit our ultrasound into many different types of devices throughout the world. Okay. That's terrific color. Thank you for all that, Joe. Maybe if I could just sort of switching lanes here. You referenced the Compass AI, and sort of the launch there. Can you maybe just expand on sort of what that does in practical terms for your moat within that focused business? What does it give you that competitors don't have today? As you sort of think about, you know, defending against some of these potential, you know, AI disruptors that are out there, how does this sort of expand the moat there? Thank you. Thank you so much, Andrew Brackmann. We were, you know, the prior team before I got here, you know, Todd Fruchterman and the team were very visionary on making sure that if Point-of-Care Ultrasound is going to be adopted enterprise-wide, that we need to manage the data. The systems, you know, the EMRs, the DICOMs, all the current hospital systems were not geared and built to operationalize Point-of-Care Ultrasound. Butterfly became the first ultrasound company that invested in an enterprise SaaS-based software that not only allowed it to collect its own data, push it into the record, push the image into DICOM, and set that record up ready to be submitted for reimbursement with the revenue cycle management software. We've built the most powerful, you know, SaaS-based system out there in order to do this. Now hospitals, when they put our software in place, they now recognize scans that weren't getting reimbursed, and they increase their revenue and profitability. It's, it's just good, and good. Now, on the other side, doctors hate new things. They don't like to have to go through new steps. They just want to do everything in their EMR. They don't want to have one software for this, one software for that. Getting to an ease-of-use paradigm is essential, because the doctors are already asked, and nurses, to do so much in their everyday lives. To now go into another platform to go through a whole other set of workflow is just something that they dread, regardless of how good it is for, you know, the patient or the economics, it's just more work. Getting our system to be easier, faster, simpler, more integrated into the, their daily workflow and to use the power of AI to where so we take their dictation. Every doctor dictates. If we can take their dictation and then pull apart the data in that dictation and populate the forms for them, you know, those 2 or 3 or 4 minutes that they save is massive to them as they and that multiplies with each patient that they see. We are very committed to making our workflow now. We've solved the major problem of connecting them and aggregating data. Now we're gonna be incessant and passionate about making it easier and easier and easier and easier for them to implement, for them to use on a daily basis, for it to be intuitive, and to let the hospitals continue to have the type of ROI they need of capturing all these images. We're never gonna stop making it, and we're gonna use every new tool available to us in AI to make it easier for our customers. Great. Thanks, guys. Appreciate the questions. Appreciate it. Thank you, Andrew. Our next question is from Ben Haynor from Lake Street Capital Markets. Your line is now open. Please go ahead. Good morning, folks. Thanks for taking the questions. Hey, Ben. For me on the, yeah, how are you? Excellent. Sounds good. Just on your own internal development, pipeline, new P5.1, you know, when should folks expect you to go to the FDA with that? Anything new on kind of the new form factors, whether that's, you know, iQ Station or, you know, in some of the wearable sort of form factors that you showed at the investor day 2 years back? Yeah. Thank you for the question. You know, we're hoping in the beginning of 2027 to have the P5.1 ship into a next program. That's kind of our timing. We think that we just sent it into production. Normally, it would take us some time, you know, late this summer to get them back, and then we start, you know, putting it into the hardware, validating, testing, and then hopefully get our clearance, and then we'll be out, you know, sometime early of 2027. That's kind of our schedule. At the same time, you know, we have a vision to bring one-to-one in hospitals and how, you know, we can make a cart-based experience with Butterfly better. iQ Station is actively on our roadmap, and it's probably a later 2027 timeframe for that. We are actively working on that program, and we think that will really codify the one-to-one model on the enterprise side. You know, we're working on making software easier, we're working to make our devices more powerful, we're working to make the workflow in the hospital easier. It's just a fate of it's just inevitable what will happen, and we're on the right path there. You know, on the wearable side, you know, if we wanted to launch a wearable tomorrow, we could, or theoretically, we could, we can put that... Wearables is not an R&D thing, it's more of a what's the use case and what's the market and what's the business? Our philosophy right now is the success of home care will determine, you know, what our wearable use case is. The more that we push ultrasound, alt site, and we push it into nursing homes, we push it into the home, and then the more we'll be, "Okay, now this is what it's being used for. This really makes sense. This is sticking, and now let's automate it, and let's make it easier, and let's put a wearable out there." You know, we have there's one of our partners, Forest Neurotech, took our technology and created a wearable. Go on their website, you'll actually see it. They put it right there. It's the technology around creating a wearable is not the challenge, it's, hey, what's the business use case? When does it make sense to invest the next several million dollars in hardware to put that out there? Our home care business, in my view, will determine the success and the timing of what is the right use case for wearables. Got it. That's very helpful. Any more you can share on that POCUS Innovators Forum that you held? That sounds like, quite the interesting event. You know, you probably need to come next year. I probably have to invite our analysts. You know, we. No problem. private the first year. The second year, we brought our whole management team and commercial team in to listen, which was a great education session. I think, you know, what's fascinating about that forum is it's not all one specialty. You have a cardiologist sitting next to an anesthesiologist, sitting next to an ER doctor, sitting next to a primary care doctor, sitting next to an intensivist, sitting next to a nurse, and sitting next to an administrator. They all have a tremendous passion for the power of being able to do a diagnosis immediately at the point of care. We all heard them present their experiences, but we also gave them a forum to tell us what they need. That's where actually Compass AI came from for the, from the last year's forum, was when they said: "It just takes too long to document each one of these records." We went now from four to five minutes down to 30 seconds. You know, we listened to them, and that's why this forum is so important. I think while we had 60 people, we had about 40 people the first year, 60 people the next year, but we'll probably open it up to, you know, 100 or more, and even maybe allow you guys to come, too. We learned a lot, and the biggest thing that we learned is that we're on the right track. If we keep listening to our customers, and being honest with ourselves on what we need to do to improve, we'll win. It was a great session, Ben. Sounds fantastic. Lastly, for me, just with Midjourney, you know, you phrase it as a revenue share potential rather than a royalty. Should folks read into that in any way? I mean, that strikes me more as a service offering rather than a device offering. No, I think you just look into this like a partnership. We are all in with them, and we are doing everything we can to make them successful, and we'll do everything we can to make them successful. We don't look at them as someone we're gonna sell chips to. We look at them as someone that we are gonna invest in, and we are gonna do everything to amplify their use case. If all of a sudden we need to do something that was not planned, we're just gonna do it because, you know, we both believe in what they're doing, and we're gonna be the best partner possible. Great. Thanks for taking the questions, guys. Awesome, Ben. Thank you. Thank you, Ben. We currently have no further questions, so I will hand back to Joe for closing remarks. Well, thank you all for being with us this morning. I know that this time of the season's busy for all our investors and analysts. I hope you can see the excitement. You know, I think the most important thing, you know, for me is, you know, we put a plan together, and we are executing to our plan. Everything that you hear on this call, there's not one surprise. Not one. Everything that we are delivering, we've told you we're gonna deliver. Everything that we are focusing on are things that we've mentioned, if not recently, you know, a year or two ago. We are executing to our plan because there's a massive opportunity in digital ultrasound. We are digital to film, and we are digital that will take over analog. It's just a fait accompli. We've put a plan in place. We are executing to it. We have an awesome team. We are beyond the time where there was doubt about the company, and the only doubt should be in that, you know, for anyone who's in our way. I appreciate your attention, and I look forward to continuing to deliver results. Thank you. Thank you, everyone. This concludes today's Butterfly Network Inc. Q4 and FY 2025 earnings call. Thank you for joining. You may now disconnect your line.

Speaker 6: Hello, everyone, thank you for joining the Butterfly Network Inc. Q4 and FY 2025 earnings call. My name is Gabrielle, I will be coordinating your call today. During the presentation, you can register a question by pressing star followed by one on your telephone keypad. If you change your mind, please press star followed by two on your telephone keypad. I will now hand over to your host, John Doherty. Please go ahead. Hello, everyone, thank you for joining the Butterfly Network Inc. Q4 and FY 2025 earnings call. hello everyone thank you for joining the butterfly network inc q4 and fy 2025 earnings call My name is Gabrielle, I will be coordinating your call today. my name is gabrielle i will be coordinating your call today During the presentation, you can register a question by pressing star followed by one on your telephone keypad. during the presentation you can register a question by pressing star followed by one on your telephone keypad If you change your mind, please press star followed by two on your telephone keypad. if you change your mind please press star followed by two on your telephone keypad I will now hand over to your host, John Doherty. i will now hand over to your host john doherty Please go ahead. please go ahead

Speaker 3: Good morning, thanks to all of you for joining our call today. Earlier, Butterfly released financial results for the fourth quarter and full year ending December 31st, 2025. We also provided a business update. The release, which includes a reconciliation of management's use of non-GAAP financial measures compared to the most applicable GAAP measures, are currently available on the Investors section of the company's website at ir.butterflynetwork.com. I, John Doherty, Chief Financial Officer of Butterfly, along with Joseph DeVivo, Butterfly's Chairman and Chief Executive Officer, will host the call this morning. During the call, we will be making certain forward-looking statements. Good morning, thanks to all of you for joining our call today. good morning thanks to all of you for joining our call today Earlier, Butterfly released financial results for the fourth quarter and full year ending December 31st, 2025. earlier butterfly released financial results for the fourth quarter and full year ending december 31st 2025 We also provided a business update. we also provided a business update The release, which includes a reconciliation of management's use of non-GAAP financial measures compared to the most applicable GAAP measures, are currently available on the Investors section of the company's website at ir.butterflynetwork.com. the release which includes a reconciliation of management's use of non-gaap financial measures compared to the most applicable gaap measures are currently available on the investors section of the company's website at ir.butterflynetwork.com I, John Doherty, Chief Financial Officer of Butterfly, along with Joseph DeVivo, Butterfly's Chairman and Chief Executive Officer, will host the call this morning. i john doherty chief financial officer of butterfly along with joseph devivo butterfly's chairman and chief executive officer will host the call this morning During the call, we will be making certain forward-looking statements. during the call we will be making certain forward-looking statements These statements may include, among other things, expectations with respect to financial results, future performance, development and commercialization of products and services, potential regulatory approvals, revenue attributable to embedded collaborations through revenue share, chip purchases or otherwise, and the size and potential growth of current or future markets for our products and services. These forward-looking statements are based on current information, assumptions, and expectations that are subject to change and involve a number of known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those contained in the forward-looking statements. These and other risks are described in our filings made with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, and the company disclaims any obligation to update such statements. As a reminder, this call is being webcast live and recorded. These statements may include, among other things, expectations with respect to financial results, future performance, development and commercialization of products and services, potential regulatory approvals, revenue attributable to embedded collaborations through revenue share, chip purchases or otherwise, and the size and potential growth of current or future markets for our products and services. these statements may include among other things expectations with respect to financial results future performance development and commercialization of products and services potential regulatory approvals revenue attributable to embedded collaborations through revenue share chip purchases or otherwise and the size and potential growth of current or future markets for our products and services These forward-looking statements are based on current information, assumptions, and expectations that are subject to change and involve a number of known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those contained in the forward-looking statements. these forward-looking statements are based on current information assumptions and expectations that are subject to change and involve a number of known and unknown risks uncertainties and other factors that may cause actual results to differ materially from those contained in the forward-looking statements These and other risks are described in our filings made with the Securities and Exchange Commission. these and other risks are described in our filings made with the securities and exchange commission You are cautioned not to place undue reliance on these forward-looking statements, and the company disclaims any obligation to update such statements. you are cautioned not to place undue reliance on these forward-looking statements and the company disclaims any obligation to update such statements As a reminder, this call is being webcast live and recorded. as a reminder this call is being webcast live and recorded To access the webcast, please visit the events section of our investor website. A replay of the event will also be available on this page following the call. I would now like to turn the call over to Joe. To access the webcast, please visit the events section of our investor website. to access the webcast please visit the events section of our investor website A replay of the event will also be available on this page following the call. a replay of the event will also be available on this page following the call I would now like to turn the call over to Joe. i would now like to turn the call over to joe

Speaker 4: Thanks, John. Good morning, everyone, and thank you for joining our fourth quarter and full year 2025 conference call. I'm pleased to announce that our fourth quarter revenues came in at $31.5 million, growing 41% year-over-year. It's also the first quarter in our history where we realized positive operating cash flow, driven by upfront payments from our Midjourney deal. We are now nearly two years into our strategic growth plan that we introduced in early 2024. The message was clear: execute with focus and financial discipline, strengthen our core franchise, and unlock the full value of our semiconductor ultrasound platform beyond handheld devices. We're doing just that, and we now have material contribution outside of our core POCUS business. Thanks, John. thanks john Good morning, everyone, and thank you for joining our fourth quarter and full year 2025 conference call. good morning everyone and thank you for joining our fourth quarter and full year 2025 conference call I'm pleased to announce that our fourth quarter revenues came in at $31.5 million, growing 41% year-over-year. i'm pleased to announce that our fourth quarter revenues came in at $31.5 million growing 41% year-over-year It's also the first quarter in our history where we realized positive operating cash flow, driven by upfront payments from our Midjourney deal. it's also the first quarter in our history where we realized positive operating cash flow driven by upfront payments from our midjourney deal We are now nearly two years into our strategic growth plan that we introduced in early 2024. we are now nearly two years into our strategic growth plan that we introduced in early 2024 The message was clear: execute with focus and financial discipline, strengthen our core franchise, and unlock the full value of our semiconductor ultrasound platform beyond handheld devices. the message was clear execute with focus and financial discipline strengthen our core franchise and unlock the full value of our semiconductor ultrasound platform beyond handheld devices We're doing just that, and we now have material contribution outside of our core POCUS business. we're doing just that and we now have material contribution outside of our core pocus business Earlier this month, Jim Cramer was asked a question about Butterfly Network on Mad Money, and he said, I quote, "It's a very competitive market, and I don't want to be in that part of the medical device group. Too hard for this guy, just too hard." You know, I'm a big fan of Jim Cramer, and like you, watch CNBC every day, and he's right about one thing: traditional medical devices are a tough sector, but Butterfly is not a traditional medical device company. We were never just a handheld company shaking at the knees of big ultrasound. We are David, faithful and committed to our cause, not backing down regardless of how large our opponent is. We are the disruptor. We are playing our own game with our own rules and our own playbook. Earlier this month, Jim Cramer was asked a question about Butterfly Network on Mad Money, and he said, I quote, "It's a very competitive market, and I don't want to be in that part of the medical device group. earlier this month jim cramer was asked a question about butterfly network on mad money and he said i quote "it's a very competitive market and i don't want to be in that part of the medical device group Too hard for this guy, just too hard." You know, I'm a big fan of Jim Cramer, and like you, watch CNBC every day, and he's right about one thing: traditional medical devices are a tough sector, but Butterfly is not a traditional medical device company. too hard for this guy just too hard." you know i'm a big fan of jim cramer and like you watch cnbc every day and he's right about one thing traditional medical devices are a tough sector but butterfly is not a traditional medical device company We were never just a handheld company shaking at the knees of big ultrasound. we were never just a handheld company shaking at the knees of big ultrasound We are David, faithful and committed to our cause, not backing down regardless of how large our opponent is. we are david faithful and committed to our cause not backing down regardless of how large our opponent is We are the disruptor. we are the disruptor We are playing our own game with our own rules and our own playbook. we are playing our own game with our own rules and our own playbook We are digital eating analog's lunch and plan to revolutionize imaging with digital ultrasound everywhere and images taken. Goliath just doesn't know it yet. We are changing ultrasound imaging with our differentiated chip platform while deploying secure cloud software, AI tools, and mobile applications, and are the only healthcare company in the world over the last seven years to receive an Apple Design Award. We are not a medical device company alone. We are a transformative semiconductor-based ultrasound company. As you're all aware, the strategy we introduced has three core tenets: accelerate our core POCUS business with an enterprise-ready, cloud-connected imaging solution, execute strategic initiatives to reach new care settings and enable entirely new applications, namely home care and Ultrasound-on-Chip co-development. Lastly, deliver an R&D roadmap that sharpens our technology edge with next-generation chips and new form factors getting more and more powerful and capable. We are digital eating analog's lunch and plan to revolutionize imaging with digital ultrasound everywhere and images taken. we are digital eating analog's lunch and plan to revolutionize imaging with digital ultrasound everywhere and images taken Goliath just doesn't know it yet. goliath just doesn't know it yet We are changing ultrasound imaging with our differentiated chip platform while deploying secure cloud software, AI tools, and mobile applications, and are the only healthcare company in the world over the last seven years to receive an Apple Design Award. we are changing ultrasound imaging with our differentiated chip platform while deploying secure cloud software ai tools and mobile applications and are the only healthcare company in the world over the last seven years to receive an apple design award We are not a medical device company alone. we are not a medical device company alone We are a transformative semiconductor-based ultrasound company. we are a transformative semiconductor-based ultrasound company As you're all aware, the strategy we introduced has three core tenets: accelerate our core POCUS business with an enterprise-ready, cloud-connected imaging solution, execute strategic initiatives to reach new care settings and enable entirely new applications, namely home care and Ultrasound-on-Chip co-development. as you're all aware the strategy we introduced has three core tenets accelerate our core pocus business with an enterprise-ready cloud-connected imaging solution execute strategic initiatives to reach new care settings and enable entirely new applications namely home care and ultrasound-on-chip co-development Lastly, deliver an R&D roadmap that sharpens our technology edge with next-generation chips and new form factors getting more and more powerful and capable. lastly deliver an r&d roadmap that sharpens our technology edge with next-generation chips and new form factors getting more and more powerful and capable Let me walk you through the progress in each of these. In core POCUS, revenue grew 15% year-over-year on top of a 35% growth in the fourth quarter of last year, which, as you recall, was a record product launch year. We closed a second large system-wide enterprise deal in the fourth quarter of 2025 and continue to deepen medical school and enterprise relationships. I'll let John cover the financials in more detail, but we feel much better about macro trends and the deal cycle than earlier in the year and expect to carry that momentum into 2026. The fourth quarter Compass AI launch is a big tailwind for our enterprise strategy. Enhancing our enterprise solution helps refresh existing accounts, continue attracting new customers and drove more than 50% growth in our enterprise pipeline since launch. Let me walk you through the progress in each of these. let me walk you through the progress in each of these In core POCUS, revenue grew 15% year-over-year on top of a 35% growth in the fourth quarter of last year, which, as you recall, was a record product launch year. in core pocus revenue grew 15% year-over-year on top of a 35% growth in the fourth quarter of last year which as you recall was a record product launch year We closed a second large system-wide enterprise deal in the fourth quarter of 2025 and continue to deepen medical school and enterprise relationships. we closed a second large system-wide enterprise deal in the fourth quarter of 2025 and continue to deepen medical school and enterprise relationships I'll let John cover the financials in more detail, but we feel much better about macro trends and the deal cycle than earlier in the year and expect to carry that momentum into 2026. i'll let john cover the financials in more detail but we feel much better about macro trends and the deal cycle than earlier in the year and expect to carry that momentum into 2026 The fourth quarter Compass AI launch is a big tailwind for our enterprise strategy. the fourth quarter compass ai launch is a big tailwind for our enterprise strategy Enhancing our enterprise solution helps refresh existing accounts, continue attracting new customers and drove more than 50% growth in our enterprise pipeline since launch. enhancing our enterprise solution helps refresh existing accounts continue attracting new customers and drove more than 50% growth in our enterprise pipeline since launch At the same time, we've been building what we believe is one of the most secure cloud infrastructures in healthcare. In the U.S., we most recently achieved GovRAMP and TX-RAMP, and FedRAMP is anticipated in the coming months, meaning we'll soon be even more qualified for cloud deployments in now the world's largest government market. Internationally, we see meaningful opportunities in 2026 as we open markets in South America and continue expanding across Middle East and Asia, alongside a renewed momentum in global health. We've surpassed 1,000 NGO partners worldwide, and many expect to increase activity in 2026. We also continue to make progress in our Butterfly Garden partners, and as you know, HeartFocus became the first FDA-cleared app in 2025, and we expected additional partners to reach that clinical milestone in 2026. At the same time, we've been building what we believe is one of the most secure cloud infrastructures in healthcare. at the same time we've been building what we believe is one of the most secure cloud infrastructures in healthcare In the U.S., we most recently achieved GovRAMP and TX-RAMP, and FedRAMP is anticipated in the coming months, meaning we'll soon be even more qualified for cloud deployments in now the world's largest government market. in the u.s we most recently achieved govramp and tx-ramp and fedramp is anticipated in the coming months meaning we'll soon be even more qualified for cloud deployments in now the world's largest government market Internationally, we see meaningful opportunities in 2026 as we open markets in South America and continue expanding across Middle East and Asia, alongside a renewed momentum in global health. internationally we see meaningful opportunities in 2026 as we open markets in south america and continue expanding across middle east and asia alongside a renewed momentum in global health We've surpassed 1,000 NGO partners worldwide, and many expect to increase activity in 2026. we've surpassed 1,000 ngo partners worldwide and many expect to increase activity in 2026 We also continue to make progress in our Butterfly Garden partners, and as you know, HeartFocus became the first FDA-cleared app in 2025, and we expected additional partners to reach that clinical milestone in 2026. we also continue to make progress in our butterfly garden partners and as you know heartfocus became the first fda-cleared app in 2025 and we expected additional partners to reach that clinical milestone in 2026 We announced plans to release our proprietary beam steering API in the first half of this year. The API will open 3D imaging capabilities that have been reserved for Butterfly products only. Because our beam steering is fully digital on a semiconductor chip and not mechanically driven like other legacy systems, we can uniquely extend those capabilities to partners. The goal is to advance what they can build, expand the AI ecosystem, and help accelerate ease of use. We're excited about the new opportunities this welcomes. Moving to the strategic growth engines. We've built a home business determined to accelerate the use of POCUS devices where the patient is, expanding the reach and empowering nurses and other clinicians to perform scans using AI tools. I believe we will reach a commercial agreement in 2026, allowing home care to enter its commercial phase. We announced plans to release our proprietary beam steering API in the first half of this year. we announced plans to release our proprietary beam steering api in the first half of this year The API will open 3D imaging capabilities that have been reserved for Butterfly products only. the api will open 3d imaging capabilities that have been reserved for butterfly products only Because our beam steering is fully digital on a semiconductor chip and not mechanically driven like other legacy systems, we can uniquely extend those capabilities to partners. because our beam steering is fully digital on a semiconductor chip and not mechanically driven like other legacy systems we can uniquely extend those capabilities to partners The goal is to advance what they can build, expand the AI ecosystem, and help accelerate ease of use. the goal is to advance what they can build expand the ai ecosystem and help accelerate ease of use We're excited about the new opportunities this welcomes. we're excited about the new opportunities this welcomes Moving to the strategic growth engines. moving to the strategic growth engines We've built a home business determined to accelerate the use of POCUS devices where the patient is, expanding the reach and empowering nurses and other clinicians to perform scans using AI tools. we've built a home business determined to accelerate the use of pocus devices where the patient is expanding the reach and empowering nurses and other clinicians to perform scans using ai tools I believe we will reach a commercial agreement in 2026, allowing home care to enter its commercial phase. i believe we will reach a commercial agreement in 2026 allowing home care to enter its commercial phase This is a powerful new channel that reduces hospital readmissions, lowers costs, and expands Butterfly's reach beyond the hospital. Home care is a reality, we think it can be a real growth driver, starting to add revenue in late 2026 and into 2027. We also ventured out to develop a new business to make our core Ultrasound-on-Chip available to companies with large new market opportunities that are not competitive with Butterfly's focus business. That was previously known as Octave. Well, to start the new year, we've officially sunset the Octave name and have centralized our semiconductor platform strategy under Butterfly Embedded, reminiscent of the Intel Inside model. What began as an adjacent effort is now emerging as a foundational business, enabling other category-defining innovators to build entirely new application on Butterfly's Ultrasound-on-Chip technology. This is a powerful new channel that reduces hospital readmissions, lowers costs, and expands Butterfly's reach beyond the hospital. this is a powerful new channel that reduces hospital readmissions lowers costs and expands butterfly's reach beyond the hospital Home care is a reality, we think it can be a real growth driver, starting to add revenue in late 2026 and into 2027. home care is a reality we think it can be a real growth driver starting to add revenue in late 2026 and into 2027 We also ventured out to develop a new business to make our core Ultrasound-on-Chip available to companies with large new market opportunities that are not competitive with Butterfly's focus business. we also ventured out to develop a new business to make our core ultrasound-on-chip available to companies with large new market opportunities that are not competitive with butterfly's focus business That was previously known as Octave. that was previously known as octave Well, to start the new year, we've officially sunset the Octave name and have centralized our semiconductor platform strategy under Butterfly Embedded, reminiscent of the Intel Inside model. well to start the new year we've officially sunset the octave name and have centralized our semiconductor platform strategy under butterfly embedded reminiscent of the intel inside model What began as an adjacent effort is now emerging as a foundational business, enabling other category-defining innovators to build entirely new application on Butterfly's Ultrasound-on-Chip technology. what began as an adjacent effort is now emerging as a foundational business enabling other category-defining innovators to build entirely new application on butterfly's ultrasound-on-chip technology The big news for the fourth quarter, though, was signing Midjourney deal in November, and as you can see today, it contributed $6.8 million of revenue in the quarter and was a key driver of our 41% year-over-year growth. Midjourney is an independent research lab pushing the boundaries of generative AI and human imagination. Their scientists have envisioned a breakthrough new application for ultrasound that we believe the world will be learning about very soon. This partnership combines Butterfly's core Ultrasound-on-Chip technology and imaging software with Midjourney's generative AI compute power to do something very special with ultrasound. This deal is more than revenue, it is validation. It's a foundational step towards Butterfly's reinvention into a platform company. The initial partnership and revenue contribution is pre-commercial. The big news for the fourth quarter, though, was signing Midjourney deal in November, and as you can see today, it contributed $6.8 million of revenue in the quarter and was a key driver of our 41% year-over-year growth. the big news for the fourth quarter though was signing midjourney deal in november and as you can see today it contributed $6.8 million of revenue in the quarter and was a key driver of our 41% year-over-year growth Midjourney is an independent research lab pushing the boundaries of generative AI and human imagination. midjourney is an independent research lab pushing the boundaries of generative ai and human imagination Their scientists have envisioned a breakthrough new application for ultrasound that we believe the world will be learning about very soon. their scientists have envisioned a breakthrough new application for ultrasound that we believe the world will be learning about very soon This partnership combines Butterfly's core Ultrasound-on-Chip technology and imaging software with Midjourney's generative AI compute power to do something very special with ultrasound. this partnership combines butterfly's core ultrasound-on-chip technology and imaging software with midjourney's generative ai compute power to do something very special with ultrasound This deal is more than revenue, it is validation. this deal is more than revenue it is validation It's a foundational step towards Butterfly's reinvention into a platform company. it's a foundational step towards butterfly's reinvention into a platform company The initial partnership and revenue contribution is pre-commercial. the initial partnership and revenue contribution is pre-commercial Based on the plan that Midjourney has shared with us, once commercial, we believe there is meaningful additional revenue opportunity for Butterfly in the form of chip sales and revenue share on top of the licensing fees that will continue through the deal. We expect this to happen in the outer years of our five-year plan, and if it occurs, could represent meaningful progress towards our goal of reaching $500 million in annual revenue by 2030. Beyond Midjourney, we signed an additional Butterfly Embedded research share partner this quarter and expect another one shortly, while managing an active pipeline of some of the largest technology and healthcare companies in the world. Before I look ahead to our R&D roadmap initiatives, I'll turn it over to John to discuss the financials. John? Based on the plan that Midjourney has shared with us, once commercial, we believe there is meaningful additional revenue opportunity for Butterfly in the form of chip sales and revenue share on top of the licensing fees that will continue through the deal. based on the plan that midjourney has shared with us once commercial we believe there is meaningful additional revenue opportunity for butterfly in the form of chip sales and revenue share on top of the licensing fees that will continue through the deal We expect this to happen in the outer years of our five-year plan, and if it occurs, could represent meaningful progress towards our goal of reaching $500 million in annual revenue by 2030. we expect this to happen in the outer years of our five-year plan and if it occurs could represent meaningful progress towards our goal of reaching $500 million in annual revenue by 2030 Beyond Midjourney, we signed an additional Butterfly Embedded research share partner this quarter and expect another one shortly, while managing an active pipeline of some of the largest technology and healthcare companies in the world. beyond midjourney we signed an additional butterfly embedded research share partner this quarter and expect another one shortly while managing an active pipeline of some of the largest technology and healthcare companies in the world Before I look ahead to our R&D roadmap initiatives, I'll turn it over to John to discuss the financials. before i look ahead to our r&d roadmap initiatives i'll turn it over to john to discuss the financials John? john

Speaker 3: Thanks, Joe. I'm very excited to have joined Joe and the talented team here at Butterfly, which includes Megan Carlson. Megan, who you all know, did a great job in the interim CFO role and has been an awesome partner to work with, along with the rest of the leadership team. With about three months behind me, I want to open with a few comments and my thoughts on Butterfly overall. I joined Butterfly because I was excited by the incredible potential this company has going forward to provide a valuable and meaningful experience to our customers, as well as to create value for our shareholders. I was also impressed by the strength of the leadership team and the passion and commitment demonstrated by employees across the company. This is a company I am proud to be a part of. Thanks, Joe. thanks joe I'm very excited to have joined Joe and the talented team here at Butterfly, which includes Megan Carlson. i'm very excited to have joined joe and the talented team here at butterfly which includes megan carlson Megan, who you all know, did a great job in the interim CFO role and has been an awesome partner to work with, along with the rest of the leadership team. megan who you all know did a great job in the interim cfo role and has been an awesome partner to work with along with the rest of the leadership team With about three months behind me, I want to open with a few comments and my thoughts on Butterfly overall. with about three months behind me i want to open with a few comments and my thoughts on butterfly overall I joined Butterfly because I was excited by the incredible potential this company has going forward to provide a valuable and meaningful experience to our customers, as well as to create value for our shareholders. i joined butterfly because i was excited by the incredible potential this company has going forward to provide a valuable and meaningful experience to our customers as well as to create value for our shareholders I was also impressed by the strength of the leadership team and the passion and commitment demonstrated by employees across the company. i was also impressed by the strength of the leadership team and the passion and commitment demonstrated by employees across the company This is a company I am proud to be a part of. this is a company i am proud to be a part of Butterfly certainly navigated a few challenges in its early years as a public company. However, the company has made the necessary difficult adjustments, including improving its operating efficiency, choosing the markets it can win in, selecting the best ways to leverage its IP and technology advantage, and allocating its resources towards higher ROI opportunities and markets. No doubt, based on these actions, Butterfly is a stronger, more agile company today. With continued steady execution, the company has the potential for significant core growth in an incredibly meaningful domain through its focused and related conscious AI software and Butterfly Garden business, and we are well positioned to gain outsized share in the markets that we compete in. We also have a significant opportunity to leverage our core platform of Ultrasound-on-Chip into other nascent and disruptive markets consistent with our strategy through Butterfly Embedded, as the Midjourney partnership demonstrates. Butterfly certainly navigated a few challenges in its early years as a public company. butterfly certainly navigated a few challenges in its early years as a public company However, the company has made the necessary difficult adjustments, including improving its operating efficiency, choosing the markets it can win in, selecting the best ways to leverage its IP and technology advantage, and allocating its resources towards higher ROI opportunities and markets. however the company has made the necessary difficult adjustments including improving its operating efficiency choosing the markets it can win in selecting the best ways to leverage its ip and technology advantage and allocating its resources towards higher roi opportunities and markets No doubt, based on these actions, Butterfly is a stronger, more agile company today. no doubt based on these actions butterfly is a stronger more agile company today With continued steady execution, the company has the potential for significant core growth in an incredibly meaningful domain through its focused and related conscious AI software and Butterfly Garden business, and we are well positioned to gain outsized share in the markets that we compete in. with continued steady execution the company has the potential for significant core growth in an incredibly meaningful domain through its focused and related conscious ai software and butterfly garden business and we are well positioned to gain outsized share in the markets that we compete in We also have a significant opportunity to leverage our core platform of Ultrasound-on-Chip into other nascent and disruptive markets consistent with our strategy through Butterfly Embedded, as the Midjourney partnership demonstrates. we also have a significant opportunity to leverage our core platform of ultrasound-on-chip into other nascent and disruptive markets consistent with our strategy through butterfly embedded as the midjourney partnership demonstrates With that, let's move on to a few highlights for the fourth quarter, including a record level of revenue for the quarter and exceeding the high end of our total revenue and adjusted EBITDA guidance ranges, a record level of quarterly probe sales, significant improvement in adjusted EBITDA margin, driven by our revenue performance and continued financial discipline, the lowest annual cash use in the company's history, and we generated positive free cash flow in the quarter, and the execution of the Midjourney contract, which helps to solidify and amplify all of our efforts to drive a new wave of ultrasound-enabled platforms and use cases through Butterfly Embedded. Let me move on to our results. We had a strong fourth quarter of 2025, with revenue of $31.5 million, the highest quarterly result in the company's history. With that, let's move on to a few highlights for the fourth quarter, including a record level of revenue for the quarter and exceeding the high end of our total revenue and adjusted EBITDA guidance ranges, a record level of quarterly probe sales, significant improvement in adjusted EBITDA margin, driven by our revenue performance and continued financial discipline, the lowest annual cash use in the company's history, and we generated positive free cash flow in the quarter, and the execution of the Midjourney contract, which helps to solidify and amplify all of our efforts to drive a new wave of ultrasound-enabled platforms and use cases through Butterfly Embedded. with that let's move on to a few highlights for the fourth quarter including a record level of revenue for the quarter and exceeding the high end of our total revenue and adjusted ebitda guidance ranges a record level of quarterly probe sales significant improvement in adjusted ebitda margin driven by our revenue performance and continued financial discipline the lowest annual cash use in the company's history and we generated positive free cash flow in the quarter and the execution of the midjourney contract which helps to solidify and amplify all of our efforts to drive a new wave of ultrasound-enabled platforms and use cases through butterfly embedded Let me move on to our results. let me move on to our results We had a strong fourth quarter of 2025, with revenue of $31.5 million, the highest quarterly result in the company's history. we had a strong fourth quarter of 2025 with revenue of $31.5 million the highest quarterly result in the company's history This represents a 41% increase year-over-year for the quarter. The increase is driven by increased revenue from Butterfly Embedded, as well as a 27% increase in year-over-year volume in our core focused business, with continued penetration of the iQ3 in all markets. The 41% year-over-year growth is significantly higher than the at least 17% year-over-year growth that we put out in January. We did better in the core business and realized more revenue from Butterfly Embedded, given the work we had already performed relative to the Midjourney contract. This is the primary reason we used the at least language at the time, as we were still finalizing the accounting treatment. Our results and the guidance I'll provide later in the call for first quarter and full year 2026 all include updated financial expectations from this contract. This represents a 41% increase year-over-year for the quarter. this represents a 41% increase year-over-year for the quarter The increase is driven by increased revenue from Butterfly Embedded, as well as a 27% increase in year-over-year volume in our core focused business, with continued penetration of the iQ3 in all markets. the increase is driven by increased revenue from butterfly embedded as well as a 27% increase in year-over-year volume in our core focused business with continued penetration of the iq3 in all markets The 41% year-over-year growth is significantly higher than the at least 17% year-over-year growth that we put out in January. the 41% year-over-year growth is significantly higher than the at least 17% year-over-year growth that we put out in january We did better in the core business and realized more revenue from Butterfly Embedded, given the work we had already performed relative to the Midjourney contract. we did better in the core business and realized more revenue from butterfly embedded given the work we had already performed relative to the midjourney contract This is the primary reason we used the at least language at the time, as we were still finalizing the accounting treatment. this is the primary reason we used the at least language at the time as we were still finalizing the accounting treatment Our results and the guidance I'll provide later in the call for first quarter and full year 2026 all include updated financial expectations from this contract. our results and the guidance i'll provide later in the call for first quarter and full year 2026 all include updated financial expectations from this contract Breaking things down between the U.S. and international channels, during the quarter, U.S. revenue was $26.8 million, which was 55% higher year-over-year, driven by revenue from Embedded, as well as strong demand in the core business, with unit sales up 44%. Total international revenue decreased by 6% year-over-year to $4.7 million in the fourth quarter. While sales of the iQ3 in the quarter were up 42% year-over-year, sales of the iQ+ were down 79%. Breaking our revenue down between product and software and other services, product revenue was $18.1 million, an increase of 23% versus the fourth quarter of 2024. Breaking things down between the U.S. and international channels, during the quarter, U.S. revenue was $26.8 million, which was 55% higher year-over-year, driven by revenue from Embedded, as well as strong demand in the core business, with unit sales up 44%. breaking things down between the u.s and international channels during the quarter u.s revenue was $26.8 million which was 55% higher year-over-year driven by revenue from embedded as well as strong demand in the core business with unit sales up 44% Total international revenue decreased by 6% year-over-year to $4.7 million in the fourth quarter. total international revenue decreased by 6% year-over-year to $4.7 million in the fourth quarter While sales of the iQ3 in the quarter were up 42% year-over-year, sales of the iQ+ were down 79%. while sales of the iq3 in the quarter were up 42% year-over-year sales of the iq+ were down 79% Breaking our revenue down between product and software and other services, product revenue was $18.1 million, an increase of 23% versus the fourth quarter of 2024. breaking our revenue down between product and software and other services product revenue was $18.1 million an increase of 23% versus the fourth quarter of 2024 This increase was driven primarily through growth in volume across all channels, with US health systems, e-com, and vet leading the way, as well as higher average selling prices in international markets with the higher mix of iQ3 sales. Software and other services revenue was $13.4 million in the fourth quarter, up 76% year-over-year. Software and other services mix was 43% of revenue, increasing from 34% in Q4 2024. This increase can be attributed to the significant step-up in revenue contribution from Butterfly Embedded in the quarter, related primarily to the Midjourney partnership. I'll talk more about this as well when I come to guidance for the first quarter and full year 2026. When looking at the full year 2025 versus 2024, total revenue increased 19% to $97.6 million. This was driven by two areas. This increase was driven primarily through growth in volume across all channels, with US health systems, e-com, and vet leading the way, as well as higher average selling prices in international markets with the higher mix of iQ3 sales. this increase was driven primarily through growth in volume across all channels with us health systems e-com and vet leading the way as well as higher average selling prices in international markets with the higher mix of iq3 sales Software and other services revenue was $13.4 million in the fourth quarter, up 76% year-over-year. software and other services revenue was $13.4 million in the fourth quarter up 76% year-over-year Software and other services mix was 43% of revenue, increasing from 34% in Q4 2024. software and other services mix was 43% of revenue increasing from 34% in q4 2024 This increase can be attributed to the significant step-up in revenue contribution from Butterfly Embedded in the quarter, related primarily to the Midjourney partnership. this increase can be attributed to the significant step-up in revenue contribution from butterfly embedded in the quarter related primarily to the midjourney partnership I'll talk more about this as well when I come to guidance for the first quarter and full year 2026. i'll talk more about this as well when i come to guidance for the first quarter and full year 2026 When looking at the full year 2025 versus 2024, total revenue increased 19% to $97.6 million. when looking at the full year 2025 versus 2024 total revenue increased 19% to $97.6 million This was driven by two areas. this was driven by two areas First, growth in our core focused business, with both increased volume and a higher average selling price, driven by an increased mix in the sales of the iQ3 and strong performance by U.S. sales, our vet channel, and international distributor channels. Second, growth in our emerging Butterfly Embedded business, primarily from the execution of the Midjourney contract in November of last year. Moving on to gross profit. Gross profit was $21.2 million in Q4 2025, a 55% increase as compared to the prior year adjusted gross profit of $13.7 million. Gross profit margin percentage increased to 67% from 61% in the prior year period. Gross margin percentage was positively impacted by the higher-margin Butterfly Embedded revenue and lower software amortization. Moving to EBITDA and cash. First, growth in our core focused business, with both increased volume and a higher average selling price, driven by an increased mix in the sales of the iQ3 and strong performance by U.S. sales, our vet channel, and international distributor channels. first growth in our core focused business with both increased volume and a higher average selling price driven by an increased mix in the sales of the iq3 and strong performance by u.s sales our vet channel and international distributor channels Second, growth in our emerging Butterfly Embedded business, primarily from the execution of the Midjourney contract in November of last year. second growth in our emerging butterfly embedded business primarily from the execution of the midjourney contract in november of last year Moving on to gross profit. moving on to gross profit Gross profit was $21.2 million in Q4 2025, a 55% increase as compared to the prior year adjusted gross profit of $13.7 million. gross profit was $21.2 million in q4 2025 a 55% increase as compared to the prior year adjusted gross profit of $13.7 million Gross profit margin percentage increased to 67% from 61% in the prior year period. gross profit margin percentage increased to 67% from 61% in the prior year period Gross margin percentage was positively impacted by the higher-margin Butterfly Embedded revenue and lower software amortization. gross margin percentage was positively impacted by the higher-margin butterfly embedded revenue and lower software amortization Moving to EBITDA and cash. moving to ebitda and cash For the fourth quarter of 2025, adjusted EBITDA loss was $3.2 million, compared with a loss of $9.1 million for the same period in 2024, an improvement of 65%. For the full year 2025, adjusted EBITDA loss was $26.5 million, compared to $38.9 million for 2024, an improvement of 32%. The improvement in adjusted EBITDA loss for both the fourth quarter and full year was driven by contribution from higher margin revenue and continued financial discipline reflected in our lower year-over-year payroll costs for the quarter and full year. For the fourth quarter of 2025, adjusted EBITDA loss was $3.2 million, compared with a loss of $9.1 million for the same period in 2024, an improvement of 65%. for the fourth quarter of 2025 adjusted ebitda loss was $3.2 million compared with a loss of $9.1 million for the same period in 2024 an improvement of 65% For the full year 2025, adjusted EBITDA loss was $26.5 million, compared to $38.9 million for 2024, an improvement of 32%. for the full year 2025 adjusted ebitda loss was $26.5 million compared to $38.9 million for 2024 an improvement of 32% The improvement in adjusted EBITDA loss for both the fourth quarter and full year was driven by contribution from higher margin revenue and continued financial discipline reflected in our lower year-over-year payroll costs for the quarter and full year. the improvement in adjusted ebitda loss for both the fourth quarter and full year was driven by contribution from higher margin revenue and continued financial discipline reflected in our lower year-over-year payroll costs for the quarter and full year This improvement in adjusted EBITDA and continued financial discipline has led to a cash and cash equivalent balance, including restricted cash at year-end of $154.5 million, and the use of cash in 2025 of $19.4 million, excluding the funds from our offering last year. This compares to a use of cash of $45.9 million in 2024, an improvement of $26.4 million. We also had positive cash flow of $6.3 million in the fourth quarter. These results demonstrate that we are very well positioned as we move forward to continue to invest in the business areas where we see significant opportunities for additional growth and disruption, including expanding our core POCUS business and penetration of Compass AI as a core operating system for health systems. This improvement in adjusted EBITDA and continued financial discipline has led to a cash and cash equivalent balance, including restricted cash at year-end of $154.5 million, and the use of cash in 2025 of $19.4 million, excluding the funds from our offering last year. this improvement in adjusted ebitda and continued financial discipline has led to a cash and cash equivalent balance including restricted cash at year-end of $154.5 million and the use of cash in 2025 of $19.4 million excluding the funds from our offering last year This compares to a use of cash of $45.9 million in 2024, an improvement of $26.4 million. this compares to a use of cash of $45.9 million in 2024 an improvement of $26.4 million We also had positive cash flow of $6.3 million in the fourth quarter. we also had positive cash flow of $6.3 million in the fourth quarter These results demonstrate that we are very well positioned as we move forward to continue to invest in the business areas where we see significant opportunities for additional growth and disruption, including expanding our core POCUS business and penetration of Compass AI as a core operating system for health systems. these results demonstrate that we are very well positioned as we move forward to continue to invest in the business areas where we see significant opportunities for additional growth and disruption including expanding our core pocus business and penetration of compass ai as a core operating system for health systems Continuing to enable third parties to build tailored ultrasound AI solutions in Butterfly Garden to provide deeper and expanded access to our platform. Expanding our home care business following the execution of our anticipated first commercial agreement, which we believe could be finalized in the first half of 2026, as Joe mentioned earlier. Enabling a new wave of Ultrasound-on-Chip-enabled technologies through Butterfly Embedded, and continued AI and semiconductor innovation with the development of our 4th-generation chip. Before turning to guidance, I want to update you on the general macroeconomic environment relative to Butterfly. While there were some concerns in 2025 relative to the government shutdown and impact on the FDA's processing of fee-based submissions, regulatory processing delays, and delays in customer purchasing decisions, we have managed through this, and it is very much behind us. Continuing to enable third parties to build tailored ultrasound AI solutions in Butterfly Garden to provide deeper and expanded access to our platform. continuing to enable third parties to build tailored ultrasound ai solutions in butterfly garden to provide deeper and expanded access to our platform Expanding our home care business following the execution of our anticipated first commercial agreement, which we believe could be finalized in the first half of 2026, as Joe mentioned earlier. expanding our home care business following the execution of our anticipated first commercial agreement which we believe could be finalized in the first half of 2026 as joe mentioned earlier Enabling a new wave of Ultrasound-on-Chip-enabled technologies through Butterfly Embedded, and continued AI and semiconductor innovation with the development of our 4th-generation chip. enabling a new wave of ultrasound-on-chip-enabled technologies through butterfly embedded and continued ai and semiconductor innovation with the development of our 4th-generation chip Before turning to guidance, I want to update you on the general macroeconomic environment relative to Butterfly. before turning to guidance i want to update you on the general macroeconomic environment relative to butterfly While there were some concerns in 2025 relative to the government shutdown and impact on the FDA's processing of fee-based submissions, regulatory processing delays, and delays in customer purchasing decisions, we have managed through this, and it is very much behind us. while there were some concerns in 2025 relative to the government shutdown and impact on the fda's processing of fee-based submissions regulatory processing delays and delays in customer purchasing decisions we have managed through this and it is very much behind us Our fourth quarter results are indicative of that, and we were able to close some of the larger deals in the pipeline and still have a number that are active. I would now like to turn to our outlook for the first quarter of 2026 and for the calendar year ending December 31st, 2026. In the first quarter, we expect revenue in the range of $24 million-$28 million, as we ended the fourth quarter somewhat higher than expected, and the first quarter is typically a slower quarter for the company due to seasonality. As is typical for Q1, adjusted EBITDA is impacted from expenses related to payroll tax and 401(k) reset, as well as our national sales meeting and POCUS Innovators Forum, which took place in January. Our fourth quarter results are indicative of that, and we were able to close some of the larger deals in the pipeline and still have a number that are active. our fourth quarter results are indicative of that and we were able to close some of the larger deals in the pipeline and still have a number that are active I would now like to turn to our outlook for the first quarter of 2026 and for the calendar year ending December 31st, 2026. i would now like to turn to our outlook for the first quarter of 2026 and for the calendar year ending december 31st 2026 In the first quarter, we expect revenue in the range of $24 million-$28 million, as we ended the fourth quarter somewhat higher than expected, and the first quarter is typically a slower quarter for the company due to seasonality. in the first quarter we expect revenue in the range of $24 million-$28 million as we ended the fourth quarter somewhat higher than expected and the first quarter is typically a slower quarter for the company due to seasonality As is typical for Q1, adjusted EBITDA is impacted from expenses related to payroll tax and 401(k) reset, as well as our national sales meeting and POCUS Innovators Forum, which took place in January. as is typical for q1 adjusted ebitda is impacted from expenses related to payroll tax and 401(k) reset as well as our national sales meeting and pocus innovators forum which took place in january As a result, we expect slightly higher expenses and higher adjusted EBITDA loss in the first quarter relative to the remainder of the year in the range of $8 million-$10 million. For the full year 2026, we expect revenues to be between $117 million and $121 million, an increase of approximately 20% to 24%. We expect our adjusted EBITDA loss to be between $21 million and $25 million. Our guidance for adjusted EBITDA includes investment in key areas to support continued innovation, as well as our emerging embedded business, as well as the impact from tariffs initiated in 2025. In summary, we had a great quarter, a record quarter. We closed the year out strong, we exceeded expectations for revenue and adjusted EBITDA, and we are very well positioned going forward. As a result, we expect slightly higher expenses and higher adjusted EBITDA loss in the first quarter relative to the remainder of the year in the range of $8 million-$10 million. as a result we expect slightly higher expenses and higher adjusted ebitda loss in the first quarter relative to the remainder of the year in the range of $8 million-$10 million For the full year 2026, we expect revenues to be between $117 million and $121 million, an increase of approximately 20% to 24%. for the full year 2026 we expect revenues to be between $117 million and $121 million an increase of approximately 20% to 24% We expect our adjusted EBITDA loss to be between $21 million and $25 million. we expect our adjusted ebitda loss to be between $21 million and $25 million Our guidance for adjusted EBITDA includes investment in key areas to support continued innovation, as well as our emerging embedded business, as well as the impact from tariffs initiated in 2025. our guidance for adjusted ebitda includes investment in key areas to support continued innovation as well as our emerging embedded business as well as the impact from tariffs initiated in 2025 In summary, we had a great quarter, a record quarter. in summary we had a great quarter a record quarter We closed the year out strong, we exceeded expectations for revenue and adjusted EBITDA, and we are very well positioned going forward. we closed the year out strong we exceeded expectations for revenue and adjusted ebitda and we are very well positioned going forward As our 2026 full year guidance indicates, we look forward to continued growth this year and beyond, and our overall outlook on the business is brighter with this past quarter reinforcing our view. In 2025, we believe the company enhanced its position in the core POCUS markets and can continue to gain share in 2026 through deeper penetration of existing customers, new customers, and applications. We also amplify our Ultrasound-on-Chip platform and the potential of Butterfly Embedded with the licensing partnership with Midjourney. We did all of this while continuing our intense focus on driving operating efficiency across the business and ROI. As I said up front, I'm excited to have joined Butterfly late last year, and I'm excited about what is ahead for the company in 2026 and beyond. Now, let me hand it back to Joe for some closing comments. As our 2026 full year guidance indicates, we look forward to continued growth this year and beyond, and our overall outlook on the business is brighter with this past quarter reinforcing our view. as our 2026 full year guidance indicates we look forward to continued growth this year and beyond and our overall outlook on the business is brighter with this past quarter reinforcing our view In 2025, we believe the company enhanced its position in the core POCUS markets and can continue to gain share in 2026 through deeper penetration of existing customers, new customers, and applications. in 2025 we believe the company enhanced its position in the core pocus markets and can continue to gain share in 2026 through deeper penetration of existing customers new customers and applications We also amplify our Ultrasound-on-Chip platform and the potential of Butterfly Embedded with the licensing partnership with Midjourney. we also amplify our ultrasound-on-chip platform and the potential of butterfly embedded with the licensing partnership with midjourney We did all of this while continuing our intense focus on driving operating efficiency across the business and ROI. we did all of this while continuing our intense focus on driving operating efficiency across the business and roi As I said up front, I'm excited to have joined Butterfly late last year, and I'm excited about what is ahead for the company in 2026 and beyond. as i said up front i'm excited to have joined butterfly late last year and i'm excited about what is ahead for the company in 2026 and beyond Now, let me hand it back to Joe for some closing comments. now let me hand it back to joe for some closing comments

Speaker 4: Thanks, John. It's an exciting time for Butterfly. We're in a strong position and are delivering on all fronts. The future is even brighter. Before closing, I'll touch briefly on R&D. We recently spent two days with 60 leading POCUS thought leaders at our annual POCUS Innovators Forum, and the alignment was unmistakable. The goals, needs, and future state vision shared was directly in line with where we are taking our portfolio. That level of synergy only strengthened our conviction that we have a path to enable every doctor and nurse with powerful, affordable, compact imaging and can meaningfully unlock enterprise adoption. As I mentioned on the last call, our fifth generation P5.1 chip was moved to production by year-end. We're excited in achieving harmonics and delivering a new level of imaging for handheld ultrasound. Thanks, John. thanks john It's an exciting time for Butterfly. it's an exciting time for butterfly We're in a strong position and are delivering on all fronts. we're in a strong position and are delivering on all fronts The future is even brighter. the future is even brighter Before closing, I'll touch briefly on R&D. before closing i'll touch briefly on r&d We recently spent two days with 60 leading POCUS thought leaders at our annual POCUS Innovators Forum, and the alignment was unmistakable. we recently spent two days with 60 leading pocus thought leaders at our annual pocus innovators forum and the alignment was unmistakable The goals, needs, and future state vision shared was directly in line with where we are taking our portfolio. the goals needs and future state vision shared was directly in line with where we are taking our portfolio That level of synergy only strengthened our conviction that we have a path to enable every doctor and nurse with powerful, affordable, compact imaging and can meaningfully unlock enterprise adoption. that level of synergy only strengthened our conviction that we have a path to enable every doctor and nurse with powerful affordable compact imaging and can meaningfully unlock enterprise adoption As I mentioned on the last call, our fifth generation P5.1 chip was moved to production by year-end. as i mentioned on the last call our fifth generation p5.1 chip was moved to production by year-end We're excited in achieving harmonics and delivering a new level of imaging for handheld ultrasound. we're excited in achieving harmonics and delivering a new level of imaging for handheld ultrasound This will open additional subspecialties and support our enterprise selling efforts in 2027 and beyond. Next up on our chip roadmap is Apollo. This new chip architecture is now receiving the full attention of our engineers and will deliver 20 times the current data rate and compute performance, ushering in a new era of digital imaging and AI. We are already working with several Butterfly Embedded partners based on the capabilities of this platform. I'd like to close by sharing exactly why I'm so excited about Butterfly's current chapter. We are pioneering semiconductor-based digital ultrasound everywhere it's needed. In the traditional ultrasound market, that means continuing to lead in point-of-care solutions that truly meet the demands in and out of the hospital, empowering doctors, nurses, and caregivers, expanding new subspecialties, strengthening our enterprise roadmap, moving imaging to the bedside and beyond it. This will open additional subspecialties and support our enterprise selling efforts in 2027 and beyond. this will open additional subspecialties and support our enterprise selling efforts in 2027 and beyond Next up on our chip roadmap is Apollo. next up on our chip roadmap is apollo This new chip architecture is now receiving the full attention of our engineers and will deliver 20 times the current data rate and compute performance, ushering in a new era of digital imaging and AI. this new chip architecture is now receiving the full attention of our engineers and will deliver 20 times the current data rate and compute performance ushering in a new era of digital imaging and ai We are already working with several Butterfly Embedded partners based on the capabilities of this platform. we are already working with several butterfly embedded partners based on the capabilities of this platform I'd like to close by sharing exactly why I'm so excited about Butterfly's current chapter. i'd like to close by sharing exactly why i'm so excited about butterfly's current chapter We are pioneering semiconductor-based digital ultrasound everywhere it's needed. we are pioneering semiconductor-based digital ultrasound everywhere it's needed In the traditional ultrasound market, that means continuing to lead in point-of-care solutions that truly meet the demands in and out of the hospital, empowering doctors, nurses, and caregivers, expanding new subspecialties, strengthening our enterprise roadmap, moving imaging to the bedside and beyond it. in the traditional ultrasound market that means continuing to lead in point-of-care solutions that truly meet the demands in and out of the hospital empowering doctors nurses and caregivers expanding new subspecialties strengthening our enterprise roadmap moving imaging to the bedside and beyond it It's also bigger than that. Ultrasound is being researched and deployed in brain therapy, continuous monitoring, robotics, organ preservation, and the list goes on. If you do a simple search of ultrasound in the magazine Nature, just this month alone shows applications in neuromodulation, ablation, antiviral therapy, and soft robotics. The real inflection point comes when ultrasound in these use cases move to silicon, when it becomes programmable, power efficient, AI native, scalable. That's the common thread. Whether it's a Butterfly handheld in a clinician's pocket, a new form factor on our roadmap driving enterprise or home adoption, or a partner building something novel with our technology that we can never do ourselves, it's the same core technology, the same architectural advantage. We are not just building devices, we are opening markets. We are enabling a new age of digital ultrasound imaging and sensing, all in one strategy. It's also bigger than that. it's also bigger than that Ultrasound is being researched and deployed in brain therapy, continuous monitoring, robotics, organ preservation, and the list goes on. ultrasound is being researched and deployed in brain therapy continuous monitoring robotics organ preservation and the list goes on If you do a simple search of ultrasound in the magazine Nature, just this month alone shows applications in neuromodulation, ablation, antiviral therapy, and soft robotics. if you do a simple search of ultrasound in the magazine nature just this month alone shows applications in neuromodulation ablation antiviral therapy and soft robotics The real inflection point comes when ultrasound in these use cases move to silicon, when it becomes programmable, power efficient, AI native, scalable. the real inflection point comes when ultrasound in these use cases move to silicon when it becomes programmable power efficient ai native scalable That's the common thread. that's the common thread Whether it's a Butterfly handheld in a clinician's pocket, a new form factor on our roadmap driving enterprise or home adoption, or a partner building something novel with our technology that we can never do ourselves, it's the same core technology, the same architectural advantage. whether it's a butterfly handheld in a clinician's pocket a new form factor on our roadmap driving enterprise or home adoption or a partner building something novel with our technology that we can never do ourselves it's the same core technology the same architectural advantage We are not just building devices, we are opening markets. we are not just building devices we are opening markets We are enabling a new age of digital ultrasound imaging and sensing, all in one strategy. we are enabling a new age of digital ultrasound imaging and sensing all in one strategy This is Butterfly. We're not just a medical device company. We're a true disruptor building the ultrasonic backbone of the AI era and one of the most exciting technology growth stories in healthcare and technology today. With that, operator, please open it up for questions. This is Butterfly. this is butterfly We're not just a medical device company. we're not just a medical device company We're a true disruptor building the ultrasonic backbone of the AI era and one of the most exciting technology growth stories in healthcare and technology today. we're a true disruptor building the ultrasonic backbone of the ai era and one of the most exciting technology growth stories in healthcare and technology today With that, operator, please open it up for questions. with that operator please open it up for questions

Speaker 6: Thank you, Joe. To ask a question, please press star followed by one on your telephone keypad now. If you change your mind, please press star followed by two. When preparing to ask your question, please ensure your device is unmuted locally. Our first question is from Josh Jennings from TD Cowen. Your line is now open. Please go ahead. Thank you, Joe. thank you joe To ask a question, please press star followed by one on your telephone keypad now. to ask a question please press star followed by one on your telephone keypad now If you change your mind, please press star followed by two. if you change your mind please press star followed by two When preparing to ask your question, please ensure your device is unmuted locally. when preparing to ask your question please ensure your device is unmuted locally Our first question is from Josh Jennings from TD Cowen. our first question is from josh jennings from td cowen Your line is now open. your line is now open Please go ahead. please go ahead

Speaker 5: Hi, good morning. Thank you. Impressive to see all the progress in so many different channels. Gives us a lot to ask about, challenging to choose one of those lanes, wanted to start with Butterfly Embedded. Hi, good morning. hi good morning Thank you. thank you Impressive to see all the progress in so many different channels. impressive to see all the progress in so many different channels Gives us a lot to ask about, challenging to choose one of those lanes, wanted to start with Butterfly Embedded. gives us a lot to ask about challenging to choose one of those lanes wanted to start with butterfly embedded

Speaker 4: Thanks, Josh. Thanks, Josh. thanks josh

Speaker 5: Absolutely, just wanted to better understand, and you may not be able to share, but any details around potential timing of the technology offering that Midjourney is going to put forward, implementing Butterfly's semiconductor and ultrasound chip technology? Any help just thinking about the cadence of revenue contributions from this partnership over the course of 2026 and what's embedded in guidance? Absolutely, just wanted to better understand, and you may not be able to share, but any details around potential timing of the technology offering that Midjourney is going to put forward, implementing Butterfly's semiconductor and ultrasound chip technology? absolutely just wanted to better understand and you may not be able to share but any details around potential timing of the technology offering that midjourney is going to put forward implementing butterfly's semiconductor and ultrasound chip technology Any help just thinking about the cadence of revenue contributions from this partnership over the course of 2026 and what's embedded in guidance? any help just thinking about the cadence of revenue contributions from this partnership over the course of 2026 and what's embedded in guidance

Speaker 4: Well, I'll let John answer the second part of that in a moment. Let me just get to the first. I think we're probably gonna see something, you know, in the relative near term from Midjourney. You know, one of the things about a Butterfly Embedded program is we are enablers for our partners. This is not our business, this is their business, and we do everything we can to amplify their business. I don't wanna get out ahead of them, and all I wanna do is do everything that we possibly can as a partner to support them. That said, I think, you know, they probably wanna get this out sooner rather than later. Well, I'll let John answer the second part of that in a moment. well i'll let john answer the second part of that in a moment Let me just get to the first. let me just get to the first I think we're probably gonna see something, you know, in the relative near term from Midjourney. i think we're probably gonna see something you know in the relative near term from midjourney You know, one of the things about a Butterfly Embedded program is we are enablers for our partners. you know one of the things about a butterfly embedded program is we are enablers for our partners This is not our business, this is their business, and we do everything we can to amplify their business. this is not our business this is their business and we do everything we can to amplify their business I don't wanna get out ahead of them, and all I wanna do is do everything that we possibly can as a partner to support them. i don't wanna get out ahead of them and all i wanna do is do everything that we possibly can as a partner to support them That said, I think, you know, they probably wanna get this out sooner rather than later. that said i think you know they probably wanna get this out sooner rather than later The moment they do, you know, we'll do the best to show you how it, you know, translates into Butterfly. John, do you want to take the second part of that? The moment they do, you know, we'll do the best to show you how it, you know, translates into Butterfly. the moment they do you know we'll do the best to show you how it you know translates into butterfly John, do you want to take the second part of that? john do you want to take the second part of that

Speaker 3: Yeah, sure. Thanks, Joe. Appreciate it. How you doing, Josh? Yeah, sure. yeah sure Thanks, Joe. thanks joe Appreciate it. appreciate it How you doing, Josh? how you doing josh

Speaker 5: Good. Good. good

Speaker 3: So- So- so-

Speaker 5: Thanks a lot. Thanks a lot. thanks a lot

Speaker 3: When you look at Embedded, you know, obviously, yeah, as Joe touched on during the opening remarks, Midjourney kind of lit it on fire, if you will, with the contract we signed at the back end of 2025. We're very excited about that contract. There's also, you know, a number of other partners that we're working with in Embedded. While right now, Embedded and our revenue is, you know, there's a big contribution from Midjourney, we do expect, you know, other contributions from other partners that we have in there, and, you know, we're really excited about what that part of our business can be, as we discussed at the back end of 2025. You know, relative to Midjourney, it's a $74 million contract, as we mentioned. There's different components of it. When you look at Embedded, you know, obviously, yeah, as Joe touched on during the opening remarks, Midjourney kind of lit it on fire, if you will, with the contract we signed at the back end of 2025. when you look at embedded you know obviously yeah as joe touched on during the opening remarks midjourney kind of lit it on fire if you will with the contract we signed at the back end of 2025 We're very excited about that contract. we're very excited about that contract There's also, you know, a number of other partners that we're working with in Embedded. there's also you know a number of other partners that we're working with in embedded While right now, Embedded and our revenue is, you know, there's a big contribution from Midjourney, we do expect, you know, other contributions from other partners that we have in there, and, you know, we're really excited about what that part of our business can be, as we discussed at the back end of 2025. while right now embedded and our revenue is you know there's a big contribution from midjourney we do expect you know other contributions from other partners that we have in there and you know we're really excited about what that part of our business can be as we discussed at the back end of 2025 You know, relative to Midjourney, it's a $74 million contract, as we mentioned. you know relative to midjourney it's a $74 million contract as we mentioned There's different components of it. there's different components of it You know, there's the upfront payment, there's annual license fees, and then there's milestone work that we do that ultimately, you know, allows us to, you know, do the, you know, take the revenue, ultimately, you know, quarter by quarter, if you, if you will, year by year. You know, we expect to get a good amount of contribution throughout 2026 into 2027 from the contract. In addition, when they commercialize, ultimately, you know, as Joe mentioned upfront as well, there's an opportunity for chip sales as well as for a revenue share as part of their business. Ultimately, really excited about the overall contribution from Midjourney, but Embedded is not just Midjourney. You know, there's the upfront payment, there's annual license fees, and then there's milestone work that we do that ultimately, you know, allows us to, you know, do the, you know, take the revenue, ultimately, you know, quarter by quarter, if you, if you will, year by year. you know there's the upfront payment there's annual license fees and then there's milestone work that we do that ultimately you know allows us to you know do the you know take the revenue ultimately you know quarter by quarter if you if you will year by year You know, we expect to get a good amount of contribution throughout 2026 into 2027 from the contract. you know we expect to get a good amount of contribution throughout 2026 into 2027 from the contract In addition, when they commercialize, ultimately, you know, as Joe mentioned upfront as well, there's an opportunity for chip sales as well as for a revenue share as part of their business. in addition when they commercialize ultimately you know as joe mentioned upfront as well there's an opportunity for chip sales as well as for a revenue share as part of their business Ultimately, really excited about the overall contribution from Midjourney, but Embedded is not just Midjourney. ultimately really excited about the overall contribution from midjourney but embedded is not just midjourney

Speaker 5: No, I appreciate that answer, and kind of leads into my next follow-up is, I mean, our understanding is that the team was focused on the Midjourney partnership and development work and then locking that in in 2025, but there were some other potential partnerships on the periphery that sounds like you guys are engaged and moving forward. Any help thinking about the Butterfly Embedded pipeline that you just referenced? No, I appreciate that answer, and kind of leads into my next follow-up is, I mean, our understanding is that the team was focused on the Midjourney partnership and development work and then locking that in in 2025, but there were some other potential partnerships on the periphery that sounds like you guys are engaged and moving forward. no i appreciate that answer and kind of leads into my next follow-up is i mean our understanding is that the team was focused on the midjourney partnership and development work and then locking that in in 2025 but there were some other potential partnerships on the periphery that sounds like you guys are engaged and moving forward Any help thinking about the Butterfly Embedded pipeline that you just referenced? any help thinking about the butterfly embedded pipeline that you just referenced

Speaker 4: Yeah. I mean, we're talking to a lot of people. As I mentioned, some, you know, very large organizations and also a lot of startup organizations. Yeah. yeah I mean, we're talking to a lot of people. i mean we're talking to a lot of people As I mentioned, some, you know, very large organizations and also a lot of startup organizations. as i mentioned some you know very large organizations and also a lot of startup organizations Kind of the way it works is, you know, we saw a, you saw a contract in the 8-K with Midjourney, in November of 2025. They had been an embedded partner for over a year prior. So the way it kind of works is, you know, people will buy a license to our software, and then they'll start buying chips, and they'll do some research. They'll do research, you know, as far as how does, you know, does a chip meet their performance that they need? How does it integrate with their systems? Then, and they do a bunch of work. You know, whenever they're done and ready, you know, if everything worked out well, then it will turn into a commercial agreement. Kind of the way it works is, you know, we saw a, you saw a contract in the 8-K with Midjourney, in November of 2025. kind of the way it works is you know we saw a you saw a contract in the 8-k with midjourney in november of 2025 They had been an embedded partner for over a year prior. they had been an embedded partner for over a year prior So the way it kind of works is, you know, people will buy a license to our software, and then they'll start buying chips, and they'll do some research. so the way it kind of works is you know people will buy a license to our software and then they'll start buying chips and they'll do some research They'll do research, you know, as far as how does, you know, does a chip meet their performance that they need? they'll do research you know as far as how does you know does a chip meet their performance that they need How does it integrate with their systems? how does it integrate with their systems Then, and they do a bunch of work. then and they do a bunch of work You know, whenever they're done and ready, you know, if everything worked out well, then it will turn into a commercial agreement. you know whenever they're done and ready you know if everything worked out well then it will turn into a commercial agreement They'll come back and say: "Okay, well, we want to now do, you know, X, Y, and Z." That's kind of how Midjourney happened. There's really no formula. It's just, you know, we have, I think, now, eight or nine embedded partners today, and the pipeline is pretty large. It's also, you know, we're not selling off-the-shelf product. You know, we have to take our product, and we have to do labs and show them how it can fit with their tech and whatnot. It is a bit of a sales process, but, you know, do we have another Midjourney in there? I hope. You know, there are some very big opportunities people are going after, massive opportunities, actually. They'll come back and say: "Okay, well, we want to now do, you know, X, Y, and Z." That's kind of how Midjourney happened. they'll come back and say "okay well we want to now do you know x y and z." that's kind of how midjourney happened There's really no formula. there's really no formula It's just, you know, we have, I think, now, eight or nine embedded partners today, and the pipeline is pretty large. it's just you know we have i think now eight or nine embedded partners today and the pipeline is pretty large It's also, you know, we're not selling off-the-shelf product. it's also you know we're not selling off-the-shelf product You know, we have to take our product, and we have to do labs and show them how it can fit with their tech and whatnot. you know we have to take our product and we have to do labs and show them how it can fit with their tech and whatnot It is a bit of a sales process, but, you know, do we have another Midjourney in there? it is a bit of a sales process but you know do we have another midjourney in there I hope. i hope You know, there are some very big opportunities people are going after, massive opportunities, actually. you know there are some very big opportunities people are going after massive opportunities actually You know, we're gonna continue to add people into the research phase of our relationships and do everything possible to meet their needs and get them, you know, committed to a commercial phase, like Midjourney did. You know, we're gonna continue to add people into the research phase of our relationships and do everything possible to meet their needs and get them, you know, committed to a commercial phase, like Midjourney did. you know we're gonna continue to add people into the research phase of our relationships and do everything possible to meet their needs and get them you know committed to a commercial phase like midjourney did

Speaker 5: Excellent. Maybe one question on the home care franchise, and it sounds like you've made progress in this first commercial partnership. I mean, what steps are left before that commercial effort kicks in? Maybe just remind us of the home POCUS market opportunity or the revenue opportunity for Butterfly in this channel. Thank you, guys, for taking all the questions. Excellent. excellent Maybe one question on the home care franchise, and it sounds like you've made progress in this first commercial partnership. maybe one question on the home care franchise and it sounds like you've made progress in this first commercial partnership I mean, what steps are left before that commercial effort kicks in? i mean what steps are left before that commercial effort kicks in Maybe just remind us of the home POCUS market opportunity or the revenue opportunity for Butterfly in this channel. maybe just remind us of the home pocus market opportunity or the revenue opportunity for butterfly in this channel Thank you, guys, for taking all the questions. thank you guys for taking all the questions

Speaker 4: Hey, thank you, Josh. Appreciate them. Yeah, I think, you know, we're pretty confident that this is going to, you know, get to a commercial conclusion. You know, as John said, in his notes, we think it'll probably happen before middle of the year, which will give us the second half of the year, to start getting it ramped up. It'd probably be nominal revenue in 2026, but start contributing in 2027. Once we get it started, and we have a line of sight, and we're able to give a better shape of what the impact is, we'll tell you as far as, you know, and incorporate it into our guidance. Hey, thank you, Josh. hey thank you josh Appreciate them. appreciate them Yeah, I think, you know, we're pretty confident that this is going to, you know, get to a commercial conclusion. yeah i think you know we're pretty confident that this is going to you know get to a commercial conclusion You know, as John said, in his notes, we think it'll probably happen before middle of the year, which will give us the second half of the year, to start getting it ramped up. you know as john said in his notes we think it'll probably happen before middle of the year which will give us the second half of the year to start getting it ramped up It'd probably be nominal revenue in 2026, but start contributing in 2027. it'd probably be nominal revenue in 2026 but start contributing in 2027 Once we get it started, and we have a line of sight, and we're able to give a better shape of what the impact is, we'll tell you as far as, you know, and incorporate it into our guidance. once we get it started and we have a line of sight and we're able to give a better shape of what the impact is we'll tell you as far as you know and incorporate it into our guidance You know, in aggregate, I think I've mentioned in the past, you know, if just this one use case we're working on, if it became a national use case, it could be a $40 million-$50 million revenue opportunity if everything went, you know, the way that we saw it. That's. You know, when we think about the amount of chronic care patients are in nursing homes and also the amount of patients that are in the home, who are being cared for by nurses, you know, as they get sicker, they need to be, you know, moved. They need to have an image. You know, in aggregate, I think I've mentioned in the past, you know, if just this one use case we're working on, if it became a national use case, it could be a $40 million-$50 million revenue opportunity if everything went, you know, the way that we saw it. you know in aggregate i think i've mentioned in the past you know if just this one use case we're working on if it became a national use case it could be a $40 million-$50 million revenue opportunity if everything went you know the way that we saw it That's. that's You know, when we think about the amount of chronic care patients are in nursing homes and also the amount of patients that are in the home, who are being cared for by nurses, you know, as they get sicker, they need to be, you know, moved. you know when we think about the amount of chronic care patients are in nursing homes and also the amount of patients that are in the home who are being cared for by nurses you know as they get sicker they need to be you know moved They need to have an image. they need to have an image You know, they have to go to the hospital, whether it's by ambulance or by some other transport, be brought up into radiology and then have, for example, a cardiac echo or something else. You know, empowering caregivers to be able to take images where they are is efficient, is low cost, and has high impact on being able to quickly give a diagnosis for a patient so their meds can be modified to make them healthier and keep them into the home, or keep them wherever they are. That is literally every facet of healthcare is about being where the patients are, being where people are, and helping them get healthier faster in the lowest cost environments. You know, our home care business is basically an extension of our POCUS business. You know, they have to go to the hospital, whether it's by ambulance or by some other transport, be brought up into radiology and then have, for example, a cardiac echo or something else. you know they have to go to the hospital whether it's by ambulance or by some other transport be brought up into radiology and then have for example a cardiac echo or something else You know, empowering caregivers to be able to take images where they are is efficient, is low cost, and has high impact on being able to quickly give a diagnosis for a patient so their meds can be modified to make them healthier and keep them into the home, or keep them wherever they are. you know empowering caregivers to be able to take images where they are is efficient is low cost and has high impact on being able to quickly give a diagnosis for a patient so their meds can be modified to make them healthier and keep them into the home or keep them wherever they are That is literally every facet of healthcare is about being where the patients are, being where people are, and helping them get healthier faster in the lowest cost environments. that is literally every facet of healthcare is about being where the patients are being where people are and helping them get healthier faster in the lowest cost environments You know, our home care business is basically an extension of our POCUS business. you know our home care business is basically an extension of our pocus business It's not a third business; it's an amplifier of POCUS. You know, ultimately everyone will figure it out, and they'll use our stuff to do all of this using the AI apps, et cetera. Home is kind of a catalyst for us to, you know, take a lot of the workflow, the logistics, and the ramp-up and the learning curve out. I've mentioned before that we think the home business can be bigger than POCUS, and the opportunities are certainly there. We have, you know, we have to prove it, and we have to get some more. Our pilot was excellent. We need to get, you know, the first few states up. We need to prove what we're doing there. We need to prove we can go to a larger geography. It's not a third business; it's an amplifier of POCUS. it's not a third business it's an amplifier of pocus You know, ultimately everyone will figure it out, and they'll use our stuff to do all of this using the AI apps, et cetera. you know ultimately everyone will figure it out and they'll use our stuff to do all of this using the ai apps et cetera Home is kind of a catalyst for us to, you know, take a lot of the workflow, the logistics, and the ramp-up and the learning curve out. home is kind of a catalyst for us to you know take a lot of the workflow the logistics and the ramp-up and the learning curve out I've mentioned before that we think the home business can be bigger than POCUS, and the opportunities are certainly there. i've mentioned before that we think the home business can be bigger than pocus and the opportunities are certainly there We have, you know, we have to prove it, and we have to get some more. we have you know we have to prove it and we have to get some more Our pilot was excellent. our pilot was excellent We need to get, you know, the first few states up. we need to get you know the first few states up We need to prove what we're doing there. we need to prove what we're doing there We need to prove we can go to a larger geography. we need to prove we can go to a larger geography It's a process, but it's a big opportunity, and it'll teach, you know, core healthcare providers and payers that point-of-care ultrasound with Butterfly is a significant way to reduce costs at the exact same time of improving quality and care for patients. It's a process, but it's a big opportunity, and it'll teach, you know, core healthcare providers and payers that point-of-care ultrasound with Butterfly is a significant way to reduce costs at the exact same time of improving quality and care for patients. it's a process but it's a big opportunity and it'll teach you know core healthcare providers and payers that point-of-care ultrasound with butterfly is a significant way to reduce costs at the exact same time of improving quality and care for patients

Speaker 6: Thank you, Josh. Our next question is from Chase Knickerbocker from Craig-Hallum. Your line is now open. Please go ahead. Thank you, Josh. thank you josh Our next question is from Chase Knickerbocker from Craig-Hallum. our next question is from chase knickerbocker from craig-hallum Your line is now open. your line is now open Please go ahead. please go ahead

Speaker 7: Good morning, guys. This is Jake on for Chase. I was wondering if you could, maybe, John, if you could give us any more color on the macro environment, if you guys are seeing any of the same trends, that affected 2025 and how they're abating now in 2026? Good morning, guys. good morning guys This is Jake on for Chase. this is jake on for chase I was wondering if you could, maybe, John, if you could give us any more color on the macro environment, if you guys are seeing any of the same trends, that affected 2025 and how they're abating now in 2026? i was wondering if you could maybe john if you could give us any more color on the macro environment if you guys are seeing any of the same trends that affected 2025 and how they're abating now in 2026

Speaker 3: Sure, and I appreciate the question. As I touched on, you know, with the opening comments, I'm not gonna say everything's behind us, but certainly, you know, we feel, you know, a lot more confident going forward. Irrespective of the Supreme Court's action relative to tariffs, you know, it's still a very. Sure, and I appreciate the question. sure and i appreciate the question As I touched on, you know, with the opening comments, I'm not gonna say everything's behind us, but certainly, you know, we feel, you know, a lot more confident going forward. as i touched on you know with the opening comments i'm not gonna say everything's behind us but certainly you know we feel you know a lot more confident going forward Irrespective of the Supreme Court's action relative to tariffs, you know, it's still a very. irrespective of the supreme court's action relative to tariffs you know it's still a very mild, say mildly, and an unpredictable area, given what happened post that. You know, we do still expect to have a bit of some downward pressure. Not a lot, but some downward pressure from tariffs. We did sign a number of contracts late in the year, so we see that things have been opening up a bit there. We still have a number of, you know, good-sized deals in the pipeline. I'd say, you know, the timing did move out kind of the back half of last year as the company had touched on when they did third quarter results, but we are seeing some improvement there. We're starting to see some things move. mild, say mildly, and an unpredictable area, given what happened post that. mild say mildly and an unpredictable area given what happened post that You know, we do still expect to have a bit of some downward pressure. you know we do still expect to have a bit of some downward pressure Not a lot, but some downward pressure from tariffs. not a lot but some downward pressure from tariffs We did sign a number of contracts late in the year, so we see that things have been opening up a bit there. we did sign a number of contracts late in the year so we see that things have been opening up a bit there We still have a number of, you know, good-sized deals in the pipeline. we still have a number of you know good-sized deals in the pipeline I'd say, you know, the timing did move out kind of the back half of last year as the company had touched on when they did third quarter results, but we are seeing some improvement there. i'd say you know the timing did move out kind of the back half of last year as the company had touched on when they did third quarter results but we are seeing some improvement there We're starting to see some things move. we're starting to see some things move Ultimately, as I mentioned, you know, the company, we're managing through it, and we don't expect it to have except for the, you know, the tariff component, we don't expect it to have a lot of impact on the company. Ultimately, as I mentioned, you know, the company, we're managing through it, and we don't expect it to have except for the, you know, the tariff component, we don't expect it to have a lot of impact on the company. ultimately as i mentioned you know the company we're managing through it and we don't expect it to have except for the you know the tariff component we don't expect it to have a lot of impact on the company

Speaker 7: Great. I appreciate that color. Apologies if I missed this, but is there any more color on the opportunity with medical schools going into the year as well for the one-to-one partnerships? Great. great I appreciate that color. i appreciate that color Apologies if I missed this, but is there any more color on the opportunity with medical schools going into the year as well for the one-to-one partnerships? apologies if i missed this but is there any more color on the opportunity with medical schools going into the year as well for the one-to-one partnerships

Speaker 4: Yeah. Medical schools, I think, should be a pretty, a pretty strong contributor to us this year. You know, the, you know, second quarter of the year is the big medical school quarter when we, when we put them all in. We have a lot of conversations for one-to-one buys, and you know, we did get a bit of a pause last year when the decision to cap student loan debt occurred, and so it caused people to pause. You know, what's so exciting about what we're doing is there is such a strong commitment for new medical students to learn ultrasound. They're actually now starting to choose where they go and the types of programs they get into based upon the commitment of building that competency. Yeah. yeah Medical schools, I think, should be a pretty, a pretty strong contributor to us this year. medical schools i think should be a pretty a pretty strong contributor to us this year You know, the, you know, second quarter of the year is the big medical school quarter when we, when we put them all in. you know the you know second quarter of the year is the big medical school quarter when we when we put them all in We have a lot of conversations for one-to-one buys, and you know, we did get a bit of a pause last year when the decision to cap student loan debt occurred, and so it caused people to pause. we have a lot of conversations for one-to-one buys and you know we did get a bit of a pause last year when the decision to cap student loan debt occurred and so it caused people to pause You know, what's so exciting about what we're doing is there is such a strong commitment for new medical students to learn ultrasound. you know what's so exciting about what we're doing is there is such a strong commitment for new medical students to learn ultrasound They're actually now starting to choose where they go and the types of programs they get into based upon the commitment of building that competency. they're actually now starting to choose where they go and the types of programs they get into based upon the commitment of building that competency You know, kids that are graduating today, and are going into their residency, completely distinguish themselves when they have this capability. Even, you know, even their, you know, their attendings, who are working with them, you know, are kind of, surprised when they see what can be done by a resident with ultrasound skills. There's not a lot of daylight out there. This is not a new thing. Students want Butterfly. They're trained on Butterfly. You know, kids that are graduating today, and are going into their residency, completely distinguish themselves when they have this capability. you know kids that are graduating today and are going into their residency completely distinguish themselves when they have this capability Even, you know, even their, you know, their attendings, who are working with them, you know, are kind of, surprised when they see what can be done by a resident with ultrasound skills. even you know even their you know their attendings who are working with them you know are kind of surprised when they see what can be done by a resident with ultrasound skills There's not a lot of daylight out there. there's not a lot of daylight out there This is not a new thing. this is not a new thing Students want Butterfly. students want butterfly They're trained on Butterfly. they're trained on butterfly They want that experience, and then when we build the brand equity with these students, they go into their residency and then into practice with that loyalty, with that understanding, and we're looking to grow with them, especially, you know, with our whole, you know, chip platform improving and getting more and more powerful, and then more apps coming in over the years. You know, we're gonna grow with them through their career. We start off with medical schools. Medical schools will be a very positive contributor in 2026. They want that experience, and then when we build the brand equity with these students, they go into their residency and then into practice with that loyalty, with that understanding, and we're looking to grow with them, especially, you know, with our whole, you know, chip platform improving and getting more and more powerful, and then more apps coming in over the years. they want that experience and then when we build the brand equity with these students they go into their residency and then into practice with that loyalty with that understanding and we're looking to grow with them especially you know with our whole you know chip platform improving and getting more and more powerful and then more apps coming in over the years You know, we're gonna grow with them through their career. you know we're gonna grow with them through their career We start off with medical schools. we start off with medical schools Medical schools will be a very positive contributor in 2026. medical schools will be a very positive contributor in 2026

Speaker 7: Appreciate the answers, guys. Thank you. Appreciate the answers, guys. appreciate the answers guys Thank you. thank you

Speaker 4: Thanks, Jake. Thanks, Jake. thanks jake

Speaker 6: Thank you. Our next question is from Andrew Brackmann, from William Blair. Your line is now open. Please go ahead. Thank you. thank you Our next question is from Andrew Brackmann, from William Blair. our next question is from andrew brackmann from william blair Your line is now open. your line is now open Please go ahead. please go ahead

Speaker 1: Hey, guys. Good morning. Hey, guys. hey guys Good morning. good morning

Speaker 4: Andrew. Andrew. andrew

Speaker 1: Thanks for taking the questions. I'll echo Josh's comments. Certainly a lot of progress here and a lot to dig into. Joe, maybe with that in mind, I'd like to start a little bit higher level. I mean, it's sort of hard to miss the underlying transformation going on here, towards Butterfly Embedded. Can you maybe just sort of talk to us about why now for this transition from med devices towards embedded and the semiconductors type of business? Then just as you sort of think about organizational focus, perhaps, are there any sort of changes in terms of your view on focus versus the opportunity with Embedded? Thanks. Thanks for taking the questions. thanks for taking the questions I'll echo Josh's comments. i'll echo josh's comments Certainly a lot of progress here and a lot to dig into. certainly a lot of progress here and a lot to dig into Joe, maybe with that in mind, I'd like to start a little bit higher level. joe maybe with that in mind i'd like to start a little bit higher level I mean, it's sort of hard to miss the underlying transformation going on here, towards Butterfly Embedded. i mean it's sort of hard to miss the underlying transformation going on here towards butterfly embedded Can you maybe just sort of talk to us about why now for this transition from med devices towards embedded and the semiconductors type of business? can you maybe just sort of talk to us about why now for this transition from med devices towards embedded and the semiconductors type of business Then just as you sort of think about organizational focus, perhaps, are there any sort of changes in terms of your view on focus versus the opportunity with Embedded? then just as you sort of think about organizational focus perhaps are there any sort of changes in terms of your view on focus versus the opportunity with embedded Thanks. thanks

Speaker 4: That's a great question, Andrew, and I actually, I probably should have emailed that to you and planted that in, because it's, that's a very appropriate question. You know, we're not trying to pivot away from focus. You know, we, you know, we wanna have every doctor and every nurse in the world, have a device that allows them to help diagnose their patients sooner, easier, low cost, where they're at. We will never, you know, move away from that vision. You know, in accomplishing that vision, Andrew, we solved the problem. We solved a major problem in technology where we can digitize, we can digitally control the ultrasound image. We can control it in a way that is much more than what medical ultrasound uses with, you know, multiple planes and depths. That's a great question, Andrew, and I actually, I probably should have emailed that to you and planted that in, because it's, that's a very appropriate question. that's a great question andrew and i actually i probably should have emailed that to you and planted that in because it's that's a very appropriate question You know, we're not trying to pivot away from focus. you know we're not trying to pivot away from focus You know, we, you know, we wanna have every doctor and every nurse in the world, have a device that allows them to help diagnose their patients sooner, easier, low cost, where they're at. you know we you know we wanna have every doctor and every nurse in the world have a device that allows them to help diagnose their patients sooner easier low cost where they're at We will never, you know, move away from that vision. we will never you know move away from that vision You know, in accomplishing that vision, Andrew, we solved the problem. you know in accomplishing that vision andrew we solved the problem We solved a major problem in technology where we can digitize, we can digitally control the ultrasound image. we solved a major problem in technology where we can digitize we can digitally control the ultrasound image We can control it in a way that is much more than what medical ultrasound uses with, you know, multiple planes and depths. we can control it in a way that is much more than what medical ultrasound uses with you know multiple planes and depths Because we control 9,000 sensors in a rectangle, which allow us to send out information, send out sound a certain way, and listen to sound a certain way. You know, what we solve for ourself for point-of-care ultrasound is a major solution for many other people out in the marketplace. You know, there is this whole concept that AI and the human body are going to merge together. You can Google it. There's a whole sci-fi fantasy out there. You know, there. If you even think of brain-computer interface, you know, Neuralink today is putting wires into the brain. There's this thing in BCI called the butcher factor, which is, you know, how many neurons do I have to kill before I get to the neuron I want to talk to? Because we control 9,000 sensors in a rectangle, which allow us to send out information, send out sound a certain way, and listen to sound a certain way. because we control 9,000 sensors in a rectangle which allow us to send out information send out sound a certain way and listen to sound a certain way You know, what we solve for ourself for point-of-care ultrasound is a major solution for many other people out in the marketplace. you know what we solve for ourself for point-of-care ultrasound is a major solution for many other people out in the marketplace You know, there is this whole concept that AI and the human body are going to merge together. you know there is this whole concept that ai and the human body are going to merge together You can Google it. you can google it There's a whole sci-fi fantasy out there. there's a whole sci-fi fantasy out there You know, there. you know there If you even think of brain-computer interface, you know, Neuralink today is putting wires into the brain. if you even think of brain-computer interface you know neuralink today is putting wires into the brain There's this thing in BCI called the butcher factor, which is, you know, how many neurons do I have to kill before I get to the neuron I want to talk to? there's this thing in bci called the butcher factor which is you know how many neurons do i have to kill before i get to the neuron i want to talk to Well, one of the beautiful things about ultrasound is, and about Butterfly, is we don't have a stagnant beam that sits in a fixed position. You know, normally, ultrasound's like a flashlight. You know, you have to move the beam in order to capture the image. We can actually, in a fixed location, move our beam and scan. If you implant something in the brain, you're gonna be able to communicate and see and listen to 25% of the entire brain or the entire lobe. It's being seen today that ultrasound is potentially a portal between AI and the human body. Well, one of the beautiful things about ultrasound is, and about Butterfly, is we don't have a stagnant beam that sits in a fixed position. well one of the beautiful things about ultrasound is and about butterfly is we don't have a stagnant beam that sits in a fixed position You know, normally, ultrasound's like a flashlight. you know normally ultrasound's like a flashlight You know, you have to move the beam in order to capture the image. you know you have to move the beam in order to capture the image We can actually, in a fixed location, move our beam and scan. we can actually in a fixed location move our beam and scan If you implant something in the brain, you're gonna be able to communicate and see and listen to 25% of the entire brain or the entire lobe. if you implant something in the brain you're gonna be able to communicate and see and listen to 25% of the entire brain or the entire lobe It's being seen today that ultrasound is potentially a portal between AI and the human body. it's being seen today that ultrasound is potentially a portal between ai and the human body Just read Nature and you'll see all these articles about brain-computer interfaces, and you'll hear about ultrasound, you'll hear about neuromodulation, you'll hear about all different types of, you know, even if it's therapeutic, people are going to be looking at the brain signals through vasculature and how vasculature flows through the brain. It ultimately, you know, you can potentially heat it and put energy. This is kind of happening. It's not like we just did a prospect, a randomized study, and we're now pushing the market. The market's calling us. Just read Nature and you'll see all these articles about brain-computer interfaces, and you'll hear about ultrasound, you'll hear about neuromodulation, you'll hear about all different types of, you know, even if it's therapeutic, people are going to be looking at the brain signals through vasculature and how vasculature flows through the brain. just read nature and you'll see all these articles about brain-computer interfaces and you'll hear about ultrasound you'll hear about neuromodulation you'll hear about all different types of you know even if it's therapeutic people are going to be looking at the brain signals through vasculature and how vasculature flows through the brain It ultimately, you know, you can potentially heat it and put energy. it ultimately you know you can potentially heat it and put energy This is kind of happening. this is kind of happening It's not like we just did a prospect, a randomized study, and we're now pushing the market. it's not like we just did a prospect a randomized study and we're now pushing the market The market's calling us. the market's calling us They see our 600 patents, they see the excellent technology that we have, and quite frankly, we have been approached prior to me getting here by companies asking to partner with them, but they were turned away because the company was trying to focus on point-of-care ultrasound. What we've said to ourselves is, "No, we've solved the foundational problem." you know, I'd hate to compare ourselves to NVIDIA because there's no way there's a scale or anywhere to draw a line. you know, from 93 to 2005, they were a video game company, and they focused on their core markets of building technologies to be better gamers, that had to be complex. They see our 600 patents, they see the excellent technology that we have, and quite frankly, we have been approached prior to me getting here by companies asking to partner with them, but they were turned away because the company was trying to focus on point-of-care ultrasound. they see our 600 patents they see the excellent technology that we have and quite frankly we have been approached prior to me getting here by companies asking to partner with them but they were turned away because the company was trying to focus on point-of-care ultrasound What we've said to ourselves is, "No, we've solved the foundational problem." you know, I'd hate to compare ourselves to NVIDIA because there's no way there's a scale or anywhere to draw a line. you know, from 93 to 2005, they were a video game company, and they focused on their core markets of building technologies to be better gamers, that had to be complex. what we've said to ourselves is "no we've solved the foundational problem." you know i'd hate to compare ourselves to nvidia because there's no way there's a scale or anywhere to draw a line you know from 93 to 2005 they were a video game company and they focused on their core markets of building technologies to be better gamers that had to be complex You know, and then with CUDA in 2006, it opened up their platform for developers who could use these incredible chips for other applications. You know, or you look at Amazon, you know, they didn't set out to become the leading cloud compute company in the world. They realized that they needed cloud compute. There wasn't a large enough vendor to take their volume. They built it themselves. When they were done, they had excess capacity, and they said, "Let's go sell that capacity." Now it's the highest profit-generating part of their business. Sometimes in business, you solve problems for your customers that benefit others, and we're just simply now allowing ourselves to work with those partners. You know, and then with CUDA in 2006, it opened up their platform for developers who could use these incredible chips for other applications. you know and then with cuda in 2006 it opened up their platform for developers who could use these incredible chips for other applications You know, or you look at Amazon, you know, they didn't set out to become the leading cloud compute company in the world. you know or you look at amazon you know they didn't set out to become the leading cloud compute company in the world They realized that they needed cloud compute. they realized that they needed cloud compute There wasn't a large enough vendor to take their volume. there wasn't a large enough vendor to take their volume They built it themselves. they built it themselves When they were done, they had excess capacity, and they said, "Let's go sell that capacity." Now it's the highest profit-generating part of their business. when they were done they had excess capacity and they said "let's go sell that capacity." now it's the highest profit-generating part of their business Sometimes in business, you solve problems for your customers that benefit others, and we're just simply now allowing ourselves to work with those partners. sometimes in business you solve problems for your customers that benefit others and we're just simply now allowing ourselves to work with those partners The beautiful part about it is that the roadmap that we've set ourselves, so, you know, our Poseidon platform, our P5.1 platform, our Apollo platform, we are now not going off and developing new things for other people and losing our focus on Point-of-Care Ultrasound. What we're actually doing is amplifying our current roadmap, and we're exposing our roadmap to those customers and those and to allow them to meet their needs. The beautiful part about it is that the roadmap that we've set ourselves, so, you know, our Poseidon platform, our P5.1 platform, our Apollo platform, we are now not going off and developing new things for other people and losing our focus on Point-of-Care Ultrasound. the beautiful part about it is that the roadmap that we've set ourselves so you know our poseidon platform our p5.1 platform our apollo platform we are now not going off and developing new things for other people and losing our focus on point-of-care ultrasound What we're actually doing is amplifying our current roadmap, and we're exposing our roadmap to those customers and those and to allow them to meet their needs. what we're actually doing is amplifying our current roadmap and we're exposing our roadmap to those customers and those and to allow them to meet their needs It actually is going to make our ability to serve point-of-care ultrasound better, and the roadmap that we have for point-of-care ultrasound and what's going to happen, you know, with our next launch of our platform, with Harmonics and P5.1, and what we're going to do with, you know, some new things that we'll unveil in 2027, there's so much synergy here, Andrew. It all ties together. We're not putting something on the shelf and then focusing someplace else. We're pulling our core tech, we're partnering with people who have real interest of building businesses and have technical challenges that we can solve. It actually is going to make our ability to serve point-of-care ultrasound better, and the roadmap that we have for point-of-care ultrasound and what's going to happen, you know, with our next launch of our platform, with Harmonics and P5.1, and what we're going to do with, you know, some new things that we'll unveil in 2027, there's so much synergy here, Andrew. it actually is going to make our ability to serve point-of-care ultrasound better and the roadmap that we have for point-of-care ultrasound and what's going to happen you know with our next launch of our platform with harmonics and p5.1 and what we're going to do with you know some new things that we'll unveil in 2027 there's so much synergy here andrew It all ties together. it all ties together We're not putting something on the shelf and then focusing someplace else. we're not putting something on the shelf and then focusing someplace else We're pulling our core tech, we're partnering with people who have real interest of building businesses and have technical challenges that we can solve. we're pulling our core tech we're partnering with people who have real interest of building businesses and have technical challenges that we can solve Instead of having an analog ultrasound device that, you know, yes, you have digital behind the lens, but then once you push the signal through the lens, that lens is cut to do one thing. Our lens can be anything, and developers love the fact that they can see the signal and then change the software, see the signal, change the software. That, you know, kind of infinite iteration cycle is how, you know, we will fit our ultrasound into many different types of devices throughout the world. Instead of having an analog ultrasound device that, you know, yes, you have digital behind the lens, but then once you push the signal through the lens, that lens is cut to do one thing. instead of having an analog ultrasound device that you know yes you have digital behind the lens but then once you push the signal through the lens that lens is cut to do one thing Our lens can be anything, and developers love the fact that they can see the signal and then change the software, see the signal, change the software. our lens can be anything and developers love the fact that they can see the signal and then change the software see the signal change the software That, you know, kind of infinite iteration cycle is how, you know, we will fit our ultrasound into many different types of devices throughout the world. that you know kind of infinite iteration cycle is how you know we will fit our ultrasound into many different types of devices throughout the world

Speaker 1: Okay. That's terrific color. Thank you for all that, Joe. Maybe if I could just sort of switching lanes here. You referenced the Compass AI, and sort of the launch there. Can you maybe just expand on sort of what that does in practical terms for your moat within that focused business? What does it give you that competitors don't have today? As you sort of think about, you know, defending against some of these potential, you know, AI disruptors that are out there, how does this sort of expand the moat there? Thank you. Okay. okay That's terrific color. that's terrific color Thank you for all that, Joe. thank you for all that joe Maybe if I could just sort of switching lanes here. maybe if i could just sort of switching lanes here You referenced the Compass AI, and sort of the launch there. you referenced the compass ai and sort of the launch there Can you maybe just expand on sort of what that does in practical terms for your moat within that focused business? can you maybe just expand on sort of what that does in practical terms for your moat within that focused business What does it give you that competitors don't have today? what does it give you that competitors don't have today As you sort of think about, you know, defending against some of these potential, you know, AI disruptors that are out there, how does this sort of expand the moat there? as you sort of think about you know defending against some of these potential you know ai disruptors that are out there how does this sort of expand the moat there Thank you. thank you

Speaker 4: Thank you so much, Andrew Brackmann. We were, you know, the prior team before I got here, you know, Todd Fruchterman and the team were very visionary on making sure that if Point-of-Care Ultrasound is going to be adopted enterprise-wide, that we need to manage the data. The systems, you know, the EMRs, the DICOMs, all the current hospital systems were not geared and built to operationalize Point-of-Care Ultrasound. Butterfly became the first ultrasound company that invested in an enterprise SaaS-based software that not only allowed it to collect its own data, push it into the record, push the image into DICOM, and set that record up ready to be submitted for reimbursement with the revenue cycle management software. Thank you so much, Andrew Brackmann. thank you so much andrew brackmann We were, you know, the prior team before I got here, you know, Todd Fruchterman and the team were very visionary on making sure that if Point-of-Care Ultrasound is going to be adopted enterprise-wide, that we need to manage the data. we were you know the prior team before i got here you know todd fruchterman and the team were very visionary on making sure that if point-of-care ultrasound is going to be adopted enterprise-wide that we need to manage the data The systems, you know, the EMRs, the DICOMs, all the current hospital systems were not geared and built to operationalize Point-of-Care Ultrasound. the systems you know the emrs the dicoms all the current hospital systems were not geared and built to operationalize point-of-care ultrasound Butterfly became the first ultrasound company that invested in an enterprise SaaS-based software that not only allowed it to collect its own data, push it into the record, push the image into DICOM, and set that record up ready to be submitted for reimbursement with the revenue cycle management software. butterfly became the first ultrasound company that invested in an enterprise saas-based software that not only allowed it to collect its own data push it into the record push the image into dicom and set that record up ready to be submitted for reimbursement with the revenue cycle management software We've built the most powerful, you know, SaaS-based system out there in order to do this. Now hospitals, when they put our software in place, they now recognize scans that weren't getting reimbursed, and they increase their revenue and profitability. It's, it's just good, and good. Now, on the other side, doctors hate new things. They don't like to have to go through new steps. They just want to do everything in their EMR. They don't want to have one software for this, one software for that. Getting to an ease-of-use paradigm is essential, because the doctors are already asked, and nurses, to do so much in their everyday lives. We've built the most powerful, you know, SaaS-based system out there in order to do this. we've built the most powerful you know saas-based system out there in order to do this Now hospitals, when they put our software in place, they now recognize scans that weren't getting reimbursed, and they increase their revenue and profitability. now hospitals when they put our software in place they now recognize scans that weren't getting reimbursed and they increase their revenue and profitability It's, it's just good, and good. it's it's just good and good Now, on the other side, doctors hate new things. now on the other side doctors hate new things They don't like to have to go through new steps. they don't like to have to go through new steps They just want to do everything in their EMR. they just want to do everything in their emr They don't want to have one software for this, one software for that. they don't want to have one software for this one software for that Getting to an ease-of-use paradigm is essential, because the doctors are already asked, and nurses, to do so much in their everyday lives. getting to an ease-of-use paradigm is essential because the doctors are already asked and nurses to do so much in their everyday lives To now go into another platform to go through a whole other set of workflow is just something that they dread, regardless of how good it is for, you know, the patient or the economics, it's just more work. Getting our system to be easier, faster, simpler, more integrated into the, their daily workflow and to use the power of AI to where so we take their dictation. Every doctor dictates. If we can take their dictation and then pull apart the data in that dictation and populate the forms for them, you know, those 2 or 3 or 4 minutes that they save is massive to them as they and that multiplies with each patient that they see. We are very committed to making our workflow now. To now go into another platform to go through a whole other set of workflow is just something that they dread, regardless of how good it is for, you know, the patient or the economics, it's just more work. to now go into another platform to go through a whole other set of workflow is just something that they dread regardless of how good it is for you know the patient or the economics it's just more work Getting our system to be easier, faster, simpler, more integrated into the, their daily workflow and to use the power of AI to where so we take their dictation. getting our system to be easier faster simpler more integrated into the their daily workflow and to use the power of ai to where so we take their dictation Every doctor dictates. every doctor dictates If we can take their dictation and then pull apart the data in that dictation and populate the forms for them, you know, those 2 or 3 or 4 minutes that they save is massive to them as they and that multiplies with each patient that they see. if we can take their dictation and then pull apart the data in that dictation and populate the forms for them you know those 2 or 3 or 4 minutes that they save is massive to them as they and that multiplies with each patient that they see We are very committed to making our workflow now. we are very committed to making our workflow now We've solved the major problem of connecting them and aggregating data. Now we're gonna be incessant and passionate about making it easier and easier and easier and easier for them to implement, for them to use on a daily basis, for it to be intuitive, and to let the hospitals continue to have the type of ROI they need of capturing all these images. We're never gonna stop making it, and we're gonna use every new tool available to us in AI to make it easier for our customers. We've solved the major problem of connecting them and aggregating data. we've solved the major problem of connecting them and aggregating data Now we're gonna be incessant and passionate about making it easier and easier and easier and easier for them to implement, for them to use on a daily basis, for it to be intuitive, and to let the hospitals continue to have the type of ROI they need of capturing all these images. now we're gonna be incessant and passionate about making it easier and easier and easier and easier for them to implement for them to use on a daily basis for it to be intuitive and to let the hospitals continue to have the type of roi they need of capturing all these images We're never gonna stop making it, and we're gonna use every new tool available to us in AI to make it easier for our customers. we're never gonna stop making it and we're gonna use every new tool available to us in ai to make it easier for our customers

Speaker 1: Great. Thanks, guys. Appreciate the questions. Great. great Thanks, guys. thanks guys Appreciate the questions. appreciate the questions

Speaker 4: Appreciate it. Appreciate it. appreciate it

Speaker 6: Thank you, Andrew. Our next question is from Ben Haynor from Lake Street Capital Markets. Your line is now open. Please go ahead. Thank you, Andrew. thank you andrew Our next question is from Ben Haynor from Lake Street Capital Markets. our next question is from ben haynor from lake street capital markets Your line is now open. your line is now open Please go ahead. please go ahead

Speaker 2: Good morning, folks. Thanks for taking the questions. Good morning, folks. good morning folks Thanks for taking the questions. thanks for taking the questions

Speaker 4: Hey, Ben. Hey, Ben. hey ben

Speaker 2: For me on the, yeah, how are you? Excellent. For me on the, yeah, how are you? for me on the yeah how are you Excellent. excellent

Speaker 4: Sounds good. Sounds good. sounds good

Speaker 2: Just on your own internal development, pipeline, new P5.1, you know, when should folks expect you to go to the FDA with that? Anything new on kind of the new form factors, whether that's, you know, iQ Station or, you know, in some of the wearable sort of form factors that you showed at the investor day 2 years back? Just on your own internal development, pipeline, new P5.1, you know, when should folks expect you to go to the FDA with that? just on your own internal development pipeline new p5.1 you know when should folks expect you to go to the fda with that Anything new on kind of the new form factors, whether that's, you know, iQ Station or, you know, in some of the wearable sort of form factors that you showed at the investor day 2 years back? anything new on kind of the new form factors whether that's you know iq station or you know in some of the wearable sort of form factors that you showed at the investor day 2 years back

Speaker 4: Yeah. Thank you for the question. You know, we're hoping in the beginning of 2027 to have the P5.1 ship into a next program. That's kind of our timing. We think that we just sent it into production. Normally, it would take us some time, you know, late this summer to get them back, and then we start, you know, putting it into the hardware, validating, testing, and then hopefully get our clearance, and then we'll be out, you know, sometime early of 2027. That's kind of our schedule. At the same time, you know, we have a vision to bring one-to-one in hospitals and how, you know, we can make a cart-based experience with Butterfly better. Yeah. yeah Thank you for the question. thank you for the question You know, we're hoping in the beginning of 2027 to have the P5.1 ship into a next program. you know we're hoping in the beginning of 2027 to have the p5.1 ship into a next program That's kind of our timing. that's kind of our timing We think that we just sent it into production. we think that we just sent it into production Normally, it would take us some time, you know, late this summer to get them back, and then we start, you know, putting it into the hardware, validating, testing, and then hopefully get our clearance, and then we'll be out, you know, sometime early of 2027. normally it would take us some time you know late this summer to get them back and then we start you know putting it into the hardware validating testing and then hopefully get our clearance and then we'll be out you know sometime early of 2027 That's kind of our schedule. that's kind of our schedule At the same time, you know, we have a vision to bring one-to-one in hospitals and how, you know, we can make a cart-based experience with Butterfly better. at the same time you know we have a vision to bring one-to-one in hospitals and how you know we can make a cart-based experience with butterfly better iQ Station is actively on our roadmap, and it's probably a later 2027 timeframe for that. We are actively working on that program, and we think that will really codify the one-to-one model on the enterprise side. You know, we're working on making software easier, we're working to make our devices more powerful, we're working to make the workflow in the hospital easier. It's just a fate of it's just inevitable what will happen, and we're on the right path there. You know, on the wearable side, you know, if we wanted to launch a wearable tomorrow, we could, or theoretically, we could, we can put that... Wearables is not an R&D thing, it's more of a what's the use case and what's the market and what's the business? iQ Station is actively on our roadmap, and it's probably a later 2027 timeframe for that. iq station is actively on our roadmap and it's probably a later 2027 timeframe for that We are actively working on that program, and we think that will really codify the one-to-one model on the enterprise side. we are actively working on that program and we think that will really codify the one-to-one model on the enterprise side You know, we're working on making software easier, we're working to make our devices more powerful, we're working to make the workflow in the hospital easier. you know we're working on making software easier we're working to make our devices more powerful we're working to make the workflow in the hospital easier It's just a fate of it's just inevitable what will happen, and we're on the right path there. it's just a fate of it's just inevitable what will happen and we're on the right path there You know, on the wearable side, you know, if we wanted to launch a wearable tomorrow, we could, or theoretically, we could, we can put that... you know on the wearable side you know if we wanted to launch a wearable tomorrow we could or theoretically we could we can put that Wearables is not an R&D thing, it's more of a what's the use case and what's the market and what's the business? wearables is not an r&d thing it's more of a what's the use case and what's the market and what's the business Our philosophy right now is the success of home care will determine, you know, what our wearable use case is. The more that we push ultrasound, alt site, and we push it into nursing homes, we push it into the home, and then the more we'll be, "Okay, now this is what it's being used for. This really makes sense. This is sticking, and now let's automate it, and let's make it easier, and let's put a wearable out there." You know, we have there's one of our partners, Forest Neurotech, took our technology and created a wearable. Go on their website, you'll actually see it. They put it right there. It's the technology around creating a wearable is not the challenge, it's, hey, what's the business use case? Our philosophy right now is the success of home care will determine, you know, what our wearable use case is. our philosophy right now is the success of home care will determine you know what our wearable use case is The more that we push ultrasound, alt site, and we push it into nursing homes, we push it into the home, and then the more we'll be, "Okay, now this is what it's being used for. the more that we push ultrasound alt site and we push it into nursing homes we push it into the home and then the more we'll be "okay now this is what it's being used for This really makes sense. this really makes sense This is sticking, and now let's automate it, and let's make it easier, and let's put a wearable out there." You know, we have there's one of our partners, Forest Neurotech, took our technology and created a wearable. this is sticking and now let's automate it and let's make it easier and let's put a wearable out there." you know we have there's one of our partners forest neurotech took our technology and created a wearable Go on their website, you'll actually see it. go on their website you'll actually see it They put it right there. they put it right there It's the technology around creating a wearable is not the challenge, it's, hey, what's the business use case? it's the technology around creating a wearable is not the challenge it's hey what's the business use case When does it make sense to invest the next several million dollars in hardware to put that out there? Our home care business, in my view, will determine the success and the timing of what is the right use case for wearables. When does it make sense to invest the next several million dollars in hardware to put that out there? when does it make sense to invest the next several million dollars in hardware to put that out there Our home care business, in my view, will determine the success and the timing of what is the right use case for wearables. our home care business in my view will determine the success and the timing of what is the right use case for wearables

Speaker 2: Got it. That's very helpful. Any more you can share on that POCUS Innovators Forum that you held? That sounds like, quite the interesting event. Got it. got it That's very helpful. that's very helpful Any more you can share on that POCUS Innovators Forum that you held? any more you can share on that pocus innovators forum that you held That sounds like, quite the interesting event. that sounds like quite the interesting event

Speaker 4: You know, you probably need to come next year. I probably have to invite our analysts. You know, we. You know, you probably need to come next year. you know you probably need to come next year I probably have to invite our analysts. i probably have to invite our analysts You know, we. you know we

Speaker 2: No problem. No problem. no problem

Speaker 4: private the first year. The second year, we brought our whole management team and commercial team in to listen, which was a great education session. I think, you know, what's fascinating about that forum is it's not all one specialty. You have a cardiologist sitting next to an anesthesiologist, sitting next to an ER doctor, sitting next to a primary care doctor, sitting next to an intensivist, sitting next to a nurse, and sitting next to an administrator. They all have a tremendous passion for the power of being able to do a diagnosis immediately at the point of care. We all heard them present their experiences, but we also gave them a forum to tell us what they need. private the first year. private the first year The second year, we brought our whole management team and commercial team in to listen, which was a great education session. the second year we brought our whole management team and commercial team in to listen which was a great education session I think, you know, what's fascinating about that forum is it's not all one specialty. i think you know what's fascinating about that forum is it's not all one specialty You have a cardiologist sitting next to an anesthesiologist, sitting next to an ER doctor, sitting next to a primary care doctor, sitting next to an intensivist, sitting next to a nurse, and sitting next to an administrator. you have a cardiologist sitting next to an anesthesiologist sitting next to an er doctor sitting next to a primary care doctor sitting next to an intensivist sitting next to a nurse and sitting next to an administrator They all have a tremendous passion for the power of being able to do a diagnosis immediately at the point of care. they all have a tremendous passion for the power of being able to do a diagnosis immediately at the point of care We all heard them present their experiences, but we also gave them a forum to tell us what they need. we all heard them present their experiences but we also gave them a forum to tell us what they need That's where actually Compass AI came from for the, from the last year's forum, was when they said: "It just takes too long to document each one of these records." We went now from four to five minutes down to 30 seconds. You know, we listened to them, and that's why this forum is so important. I think while we had 60 people, we had about 40 people the first year, 60 people the next year, but we'll probably open it up to, you know, 100 or more, and even maybe allow you guys to come, too. We learned a lot, and the biggest thing that we learned is that we're on the right track. That's where actually Compass AI came from for the, from the last year's forum, was when they said: "It just takes too long to document each one of these records." We went now from four to five minutes down to 30 seconds. that's where actually compass ai came from for the from the last year's forum was when they said "it just takes too long to document each one of these records." we went now from four to five minutes down to 30 seconds You know, we listened to them, and that's why this forum is so important. you know we listened to them and that's why this forum is so important I think while we had 60 people, we had about 40 people the first year, 60 people the next year, but we'll probably open it up to, you know, 100 or more, and even maybe allow you guys to come, too. i think while we had 60 people we had about 40 people the first year 60 people the next year but we'll probably open it up to you know 100 or more and even maybe allow you guys to come too We learned a lot, and the biggest thing that we learned is that we're on the right track. we learned a lot and the biggest thing that we learned is that we're on the right track If we keep listening to our customers, and being honest with ourselves on what we need to do to improve, we'll win. It was a great session, Ben. If we keep listening to our customers, and being honest with ourselves on what we need to do to improve, we'll win. if we keep listening to our customers and being honest with ourselves on what we need to do to improve we'll win It was a great session, Ben. it was a great session ben

Speaker 2: Sounds fantastic. Lastly, for me, just with Midjourney, you know, you phrase it as a revenue share potential rather than a royalty. Should folks read into that in any way? I mean, that strikes me more as a service offering rather than a device offering. Sounds fantastic. sounds fantastic Lastly, for me, just with Midjourney, you know, you phrase it as a revenue share potential rather than a royalty. lastly for me just with midjourney you know you phrase it as a revenue share potential rather than a royalty Should folks read into that in any way? should folks read into that in any way I mean, that strikes me more as a service offering rather than a device offering. i mean that strikes me more as a service offering rather than a device offering

Speaker 4: No, I think you just look into this like a partnership. We are all in with them, and we are doing everything we can to make them successful, and we'll do everything we can to make them successful. We don't look at them as someone we're gonna sell chips to. We look at them as someone that we are gonna invest in, and we are gonna do everything to amplify their use case. If all of a sudden we need to do something that was not planned, we're just gonna do it because, you know, we both believe in what they're doing, and we're gonna be the best partner possible. No, I think you just look into this like a partnership. no i think you just look into this like a partnership We are all in with them, and we are doing everything we can to make them successful, and we'll do everything we can to make them successful. we are all in with them and we are doing everything we can to make them successful and we'll do everything we can to make them successful We don't look at them as someone we're gonna sell chips to. we don't look at them as someone we're gonna sell chips to We look at them as someone that we are gonna invest in, and we are gonna do everything to amplify their use case. we look at them as someone that we are gonna invest in and we are gonna do everything to amplify their use case If all of a sudden we need to do something that was not planned, we're just gonna do it because, you know, we both believe in what they're doing, and we're gonna be the best partner possible. if all of a sudden we need to do something that was not planned we're just gonna do it because you know we both believe in what they're doing and we're gonna be the best partner possible

Speaker 2: Great. Thanks for taking the questions, guys. Great. great Thanks for taking the questions, guys. thanks for taking the questions guys

Speaker 4: Awesome, Ben. Thank you. Awesome, Ben. awesome ben Thank you. thank you

Speaker 6: Thank you, Ben. We currently have no further questions, so I will hand back to Joe for closing remarks. Thank you, Ben. thank you ben We currently have no further questions, so I will hand back to Joe for closing remarks. we currently have no further questions so i will hand back to joe for closing remarks

Speaker 4: Well, thank you all for being with us this morning. I know that this time of the season's busy for all our investors and analysts. I hope you can see the excitement. You know, I think the most important thing, you know, for me is, you know, we put a plan together, and we are executing to our plan. Everything that you hear on this call, there's not one surprise. Not one. Everything that we are delivering, we've told you we're gonna deliver. Everything that we are focusing on are things that we've mentioned, if not recently, you know, a year or two ago. We are executing to our plan because there's a massive opportunity in digital ultrasound. We are digital to film, and we are digital that will take over analog. It's just a fait accompli. Well, thank you all for being with us this morning. well thank you all for being with us this morning I know that this time of the season's busy for all our investors and analysts. i know that this time of the season's busy for all our investors and analysts I hope you can see the excitement. i hope you can see the excitement You know, I think the most important thing, you know, for me is, you know, we put a plan together, and we are executing to our plan. you know i think the most important thing you know for me is you know we put a plan together and we are executing to our plan Everything that you hear on this call, there's not one surprise. everything that you hear on this call there's not one surprise Not one. not one Everything that we are delivering, we've told you we're gonna deliver. everything that we are delivering we've told you we're gonna deliver Everything that we are focusing on are things that we've mentioned, if not recently, you know, a year or two ago. everything that we are focusing on are things that we've mentioned if not recently you know a year or two ago We are executing to our plan because there's a massive opportunity in digital ultrasound. we are executing to our plan because there's a massive opportunity in digital ultrasound We are digital to film, and we are digital that will take over analog. we are digital to film and we are digital that will take over analog It's just a fait accompli. it's just a fait accompli We've put a plan in place. We are executing to it. We have an awesome team. We are beyond the time where there was doubt about the company, and the only doubt should be in that, you know, for anyone who's in our way. I appreciate your attention, and I look forward to continuing to deliver results. Thank you. We've put a plan in place. we've put a plan in place We are executing to it. we are executing to it We have an awesome team. we have an awesome team We are beyond the time where there was doubt about the company, and the only doubt should be in that, you know, for anyone who's in our way. we are beyond the time where there was doubt about the company and the only doubt should be in that you know for anyone who's in our way I appreciate your attention, and I look forward to continuing to deliver results. i appreciate your attention and i look forward to continuing to deliver results Thank you. thank you

Speaker 6: Thank you, everyone. This concludes today's Butterfly Network Inc. Q4 and FY 2025 earnings call. Thank you for joining. You may now disconnect your line. Thank you, everyone. thank you everyone This concludes today's Butterfly Network Inc. Q4 and FY 2025 earnings call. this concludes today's butterfly network inc q4 and fy 2025 earnings call Thank you for joining. thank you for joining You may now disconnect your line. you may now disconnect your line